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4Foreword
The present report was prepared by Professor Linda Nielsen, PhD, and Berit A. Faber, Head of
Secretariat, L.L.M, in collaboration with the BioTIK Secretariat, the National Consumer Agency of
Denmark. During the preliminary research and final preparation of the report, Gisela Hildebrandt and
Troels Koch, students of law, provided skilled and dedicated assistance with Internet searching and
typing up of the final document. 
The purpose of the report is to describe, analyse and assess the varying methods of operationali-
sing ethical principles within European regulation of biotechnology, with the inclusion of proposals for
different tools and models for use in future regulation. The aim of the report is first and foremost to
serve as a practical resource for use in evolving regulation, political support, and democratic and
debating activities in different domains in response to rapid advances in biotechnology, and the ethi-
cal concerns that follow in its wake. Accordingly, we have chosen to provide only a limited number of
notes to document sources. The individual statements are expanded on in the report’s appendices,
where further documentation is provided. We hope that the report will contribute to supporting the
aim of developing the life sciences and biotechnology in accordance with ethical values and societal
aims, in line with the description in the EU Commission’s strategy on ”Life Sciences and
Biotechnology - A Strategy for Europe”, as now ratified by the EU’s Council of Ministers. The EU
Commission’s strategy for life sciences and biotechnology testifies to the fact that deliberations on
operationalisation of the ethical principles which biotechnology raises are currently ongoing in many
countries and at many levels, and it is our hope that this report with its ”toolbox”, ”buffet” and
”menu” may serve to consolidate and inspire these deliberations.
Ethical principles in european regulation of biotechnology | Linda Nielsen | Berit A. Faber| April 2002
031 Lilla rapport  03/09/02  14:19  Side 4





2 ETHICS AND ACTORS 12
2.1 Fundamental ethical principles 12
2.1.1 Economic and qualitative benefits 12
2.1.2 Autonomy, dignity, integrity and vulnerability 12
2.1.3 Just distribution of benefits and burdens 12
2.1.4 Co-determination and openness 12
2.1.5 General deliberations on the regulation of ethical issues 12
2.2 Different actors 13
2.2.1 Researchers, commercial actors and other affected parties 13
2.2.2 Decision-makers and administrators 14
2.2.3 The media and the general public/lay people 14
3 RISK ASSESSMENT - BETWEEN SCIENCE AND VALUES 15
3.1 Beyond the objective risk concept 15
3.2 Biotechnology as a risk narrative 16
3.3 The communication of risk as a dialogue about uncertainty 18
PART TWO: Regulation of biotechnology at international 
and national level
4 REGULATION - OVERVIEW 22
4.1 International regulation 22
4.2 The Council of Europe 23
4.3 The EU: 23
4.3.1 The authorisation system for medicinal products 23
4.3.2 EU authorisation system for GMOs, plants and foods 24
4.3.3 Other EU regulation, etc. 25
4.4 National regulation in the field of health 26
4.5 The international picture and differences in the intensity of national 
regulatory activity 27
Contents
Ethical principles in european regulation of biotechnology | Linda Nielsen | Berit A. Faber| April 2002
031 Lilla rapport  03/09/02  14:19  Side 5
65 ANALYSIS OF THE REGULATORY PICTURE 29
5.1 ”Ethics where?” - coverage and scope of ethical principles 29
5.2 Medicinal products, plants and foods - ethics 30
5.3 The ”ethics of how?” - different models for operationalisation 30
5.3.1 Broad, discretionary or precise provisions 30
5.3.2 Regulation of content versus process 33
5.4 Incorporation of the four ethical principles 33
5.5 Summarising analysis - ”gaps in Community regulation” 34
PART THREE: Tools for incorporating ethical principles
6 DEMOCRATISATION TOOLS AND DEBATE MODELS 38
6.1 Ethical councils (debate and advice) 38
6.1.1 Nomination and members 38
6.1.2 Objective 39
6.2 Scientific ethics committees (authorisations) 39
6.2.1 The committees’ composition 39
6.2.2 Areas of responsibility 40
6.2.3 Assessment criteria 40
6.3 Other democratisation tools 41
6.3.1 Technology councils, including consensus conferences 41
6.3.2 Future panel 41
6.3.3 Values workshop - Norway 41
6.4 Cooperation between councils and boards 42
6.5 Analysis and evaluation of democratisation instruments 43
6.5.1 Representation of experts and of lay people 43
6.5.2 The purpose and role of the committees 45
6.5.3 Criteria for ethical evaluation 46
7 REGULATORY INSTRUMENTS 47
7.1 Regulatory function 47
7.1.1 The normative function 47
7.1.2 The protective function 47
7.1.3 The technical function 47
7.2 Different types of regulatory instruments 48
7.3 Advantages and drawbacks of different regulatory models 49
Ethical principles in european regulation of biotechnology | Linda Nielsen | Berit A. Faber| April 2002
031 Lilla rapport  03/09/02  14:19  Side 6
78 THE TOOLBOX - CHECK-LIST 52
8.1 Regulatory models 52
8.1.1 Choice of forum 52
8.1.2 Choice of type 52
8.2 Debate models 53
8.2.1 Consensus conferences etc. 53
PART FOUR: Ethical principles in European regulation
9 CONCLUSIONS AND RECOMMENDATIONS 56
9.1 Introduction 56
9.2 Can experience from the human area be applied to the foods area? 56
9.3 Ethical principles in the foods area? 59
9.4 How are ethical principles operationalised in regulations? 60
9.4.1 Regulatory challenges and possible tools 60
9.4.2 Political will and regulatory scope 61
9.4.3 Actors: role and scope of action 62
9.4.4 Debate: polycentrism and timing 65
9.5 A choice of tools 65
9.5.1 The debate models 65
9.5.2 National regulation 66
9.5.3 International regulation 66
9.6 Conclusion 67
10 PROSPECTS AND CHALLENGES 70
11 POSTSCRIPT 71 
Ethical principles in european regulation of biotechnology | Linda Nielsen | Berit A. Faber| April 2002
031 Lilla rapport  03/09/02  14:19  Side 7
031 Lilla rapport  03/09/02  14:19  Side 8
9Ethical principles in european regulation of biotechnology | Linda Nielsen | Berit A. Faber | April 2002
• Ethical principles
• Different actors
• Risk assessment - 




031 Lilla rapport  03/09/02  14:19  Side 9
10
Ethical principles in european regulation of biotechnology | Linda Nielsen | Berit A. Faber | April 2002
1 Introduction
Biotechnology, bioethics and biolaw are  impor-
tant issues on the agenda both nationally and
internationally - and not least with regard to
the EU. One of the reasons for this is the trans-
cendental nature of biotechnology as concerns
national borders, impacts and cultures. It offers
hope of major breakthroughs in a wide range of
areas, but, equally, gives rise to concerns
about the negative impacts and breaches of
fundamental ethical values that it may entail. A
series of questions therefore arise about how
the positive aspects of biotechnology may be
put to use and supported while, at the same
time, avoiding potentially undesirable aspects
and impacts. In this sense, ethical principles in
Community regulation of biotechnology are a
central issue.
Bioethics can help to provide pointers as to
which applications and impacts are to be consi-
dered either desirable or undesirable.
Regulation can then help to impose limits on
the application of biotechnology on the basis of
these ethical principles, and to ensure that the
governance and control of such application take
place in accordance with democratic values,
such as dialogue, participation and equity. In
this way, regulation reflects ethics, while also
serving to guide ethical evaluation.
1.1 Background
The new biotechnologies, involving genetic eng-
ineering and cloning as well as genetically
modified organisms (GMOs), raise a large num-
ber of new and difficult questions about how
these technologies are to be tackled - from a
political, ethical and legal perspective.  We are
faced with a melting pot in which ethical ques-
tions and the prospects for governance of
human health, food and the environment, as
well as the rights of different individuals and
groups intermingle and become interdepen-
dent. The ethical principles have to be weighed
against each other and operationalised in regu-
lation. This process is exceptionally difficult, but
is increasingly necessary in a growing number
of areas.
The EU has a central role in the process, both
by virtue of its directives and its ethics commit-
tees and debates in the European Parliament.
Matters of special importance include the EU’s
role vis-à-vis the moratorium on GM products,
the precautionary principle, the Charter of
Fundamental Rights and regulation of the mar-
keting of foods and medicinal products. At the
same time, in recent years, regulation has
been introduced in a large number of EU mem-
ber states, which, with varying aims and inten-
sity and employing different means, has sought
to strike a balance between promoting and
controlling biotechnology.
1.2 Purpose
The purpose of this report is to describe, analy-
se and assess the varying methods of operatio-
nalising ethical principles within European regu-
lation of biotechnology, with the inclusion of
proposals for different tools and models for use
in future regulation.
Part One describes the issues, and presents
the ethical principles involved. The fundamental
dilemmas inherent in operationalising ethical
principles in regulation in one way or another
are also introduced; similarly, the actors pre-
sent in the area and the way in which risk
assessment is situated between science and
values are also covered.
Part Two outlines regulation in the field of bio-
technology in the EU. The aim here is not to
offer an exhaustive description of the particu-
lars of regulation, but to offer an at-a-glance
view, which, it is hoped, will facilitate delibera-
tions on regulatory models from a broader per-
spective. The outline covers general internatio-
nal regulation, including regulation ratified by
the European Union, as well as a kaleidoscopic
picture of national regulation in the individual
EU member states. Additionally, we provide a
brief walk-through of regulation in the different
fields of biotechnology, since regulation varies
considerably according to the issue it covers,
e.g. medically assisted procreation or foods,
etc. Attention will be drawn to the principal
common denominators and differences.
Part Three describes a range of tools for
operationalising ethical principles, and the
advantages and drawbacks of individual tools
are described and assessed. The report covers
tools for democratising the decision-making
process (”debate models”), traditional regulato-
ry instruments (legal acts, administrative direc-
tives and the like), as well as other instru-
ments, including case law, professional stan-
dards and education. We then go on to provide
a ”check-list” for a number of the decisions that
need to be made with respect to choice of
forum, form and content of regulation and/or
the democratic process whereby the ethical
principles are to be operationalised. The various
options are presented metaphorically in the
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form of a ”buffet” of different ”dishes” for com-
posing a complete ”meal”.
Part Four focuses on how the ”toolbox” can be
employed constructively. In this context we will
be considering how lessons learned in the
”human health area” e.g. the treatment of pati-
ents and scientific ethical evaluations, might be
incorporated in the foods area. Drawing on the
analysis of the advantages and drawbacks of
the various tools, a series of different proposals
for solutions will be indicated. In recognition of
the fact that different countries have different
backgrounds and traditions as regards culture,
religion, structures, regulatory traditions and so
on, the aim is not to dictate the ”correct” use
of the toolbox, but to propose a range of
options. In other words, we return to the idea
of a ”menu” from which alternative ”meals”
may be assembled. 
For the Danish version of the report, an appen-
dix section is provided, which includes a more
detailed report on legislation in the area, a list
of links and an overview of selected ethical pro-
visions from the EU regulation of medicinal pro-
ducts and foods. The last of these appendices
is in English. 
1.3 Methods
Relevant, up-to-date legislation on selected bio-
technology areas for selected countries has
been collated. Since this regulation is evolving
rapidly and is subject to frequent amendment,
a detailed description of legislation in the ind-
ividual countries has not been attempted, but
instead a panoramic view, as a means of obtai-
ning a general perspective. As a dynamic, prac-
ticable aid to finding the relevant regulation,
etc. Appendix 1 contains a collection of links to
the appropriate websites.
The selected areas comprise legislation of
medically assisted procreation, genetic testing
and gene therapy, biobanks, medical research
and clinical trials involving humans, cloning,
genetically modified animals, xenotransplanta-
tion and genetically modified foods. The coun-
tries selected for detailed study are the UK,
France, Germany, Sweden, The Netherlands,
Denmark and Norway (even though Norway is
outside the EU).
The report is to a large degree based on our
experience as legal experts, which includes
participation over many years in legislative
work within the Danish framework, collabora-
tion on bioethics and regulation at the Nordic 
level, and legal work under the auspices of the
EU and in relation to the Council of Europe. At
the same time, we have worked for many years
with ethical issues, both as President/Head of
Secretariat of the Danish Council of Ethics and
in relation to the EU (as a member of EGE) and
the Council of Europe (participation in the con-
sultations on the Convention on Human Rights
and Biomedicine). Finally, we have attended a
large number of conferences, seminars, etc. on
biolaw and bioethics at the international level. 
The deliberations on the advantages and draw-
backs, experiences, etc. of different tools are
based partly on our own experiences, and part-
ly on a series of discussions over the years with
a range of people familiar with the area. It fol-
lows that no attempt is made to present scien-
tific truths, but rather a number of opinions,
which may often be subjective, and which may
be expressed differently outside the country
that originally produced a given instrument.
Nonetheless, we have felt it appropriate to
include these reflections, since, it is hoped,
they may aid the process of selecting tools and
menus.
The aim of the report is first and foremost to
serve as a practical resource for use in evolving
regulation, political support, and democratic
and debating activities in different domains in
response to rapid advances in biotechnology,
and the ethical concerns that follow in its wake.
Accordingly, we have chosen to provide only a
limited number of notes to document sources,
etc. The individual statements are expanded on
in the report’s appendices, where further docu-
mentation is provided. 
We hope that the report will contribute to
supporting the aim of developing the life scien-
ces and biotechnology in accordance with ethi-
cal values and societal aims, in line with the
description in the EU Commission’s strategy on
”Life Sciences and Biotechnology - A Strategy
for Europe”, as now ratified by the EU’s Council
of Ministers.
The EU Commission’s strategy for life scien-
ces and biotechnology testifies to the fact that
deliberations on operationalisation of the ethical
principles which biotechnology raises are cur-
rently ongoing in many countries and at many
levels, and it is our hope that this report with
its ”toolbox”, ”buffet” and ”menu” may serve to
consolidate and inspire these deliberations. 
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2 Ethics and actors
2.1 Fundamental ethical principles
There can be little doubt that biotechnology
heralds substantial prospects for the positive
development of both national and international
society, yet our ability to unlock these potenti-
als is conditional on our response to a number
of key ethical issues. One of the most funda-
mental aspects is the need to incorporate the
ethical principles borne out of concerns about
how biotechnology might impact on values and
rights in a way that is considered undesirable.
Biotechnology confronts us with a range of
ethical and political challenges by putting the
focus on fundamental human values. Once the
individual person, profession, clinic, or country,
or the European Union, etc. assumes a stance
on how biotechnology is to be utilised, ethical
evaluations become essential. 
Since the focus in this report is devoted especi-
ally to ”tools” for incorporating ethical princi-
ples, no thoroughgoing description and analysis
is made of the diversity of ethical viewpoints
and positions that exist within the scientific
debate on this question.1 This should also be
seen in the light of the fact that, within natio-
nal boundaries, there will be internal debates
on how ethics are to be defined and implemen-
ted in detail, just as at the international level
there is a difference in which ethical schools
and movements are most prominent. It is,
however, necessary to specify which elements
these ethical principles contain in each case.
This is a question of a choice, which is open to
discussion, but which nonetheless is judged to
include the most important elements to have
gained a foothold in current ethical science and
literature. The ethical signposts employed in
the following can be divided into four ”sets”:2
2.1.1 Economic and 
qualitative benefits
Biotechnology is to be employed for the benefit
of human beings, society and nature. There is,
therefore, an assumption that, for any potential
risk to be acceptable, the technology should
not simply serve financial interests, but also
contribute to an improved quality of life, e.g. in
the shape of better foods, an improved envi-
ronment or better health.
2.1.2 Autonomy, dignity, 
integrity and vulnerability
In the application of biotechnology, regard must
be shown for human autonomy and dignity and
for the integrity and vulnerability of human
beings, animals and the natural world.
2.1.3 Just distribution 
of benefits and burdens
Biotechnology should be employed in such a
way that it does not impede our efforts to crea-
te a society in which benefits and burdens are
fairly distributed. This consideration applies
both within the individual society and in rela-
tion to the creation of growth which is sustai-
nable when seen in relation to other countries,




Decisions to use or not to employ genetic eng-
ineering should be made through an open pro-
cess, where respect is given to all viewpoints.
These four fundamental principles should be
understood as parameters to be made substan-
tive and operationalised through democratic
debate. Decisions on the utilisation of biotech-
nology will often be the result of a series of
complicated balances, and these balances may
differ within different aspects of life, from coun-
try to country, and within different professions
and cultures.
2.1.5 General deliberations on the
regulation of ethical issues
Ethical issues may be embodied in legislative
regulation in two basic ways. Firstly, ethical
considerations can lead to standardisation of
content, such that the administrative authoriti-
es can instantly determine, on the basis of
ethical rules in the legislation, whether somet-
hing is prohibited or is permissible. An example
of this would be the prohibition of cloning.
Secondly, ethical issues may be embodied in
standardisation of procedure, such that the
administrative authorities need to make a
ruling on whether something is prohibited or
can be permitted, after a closer examination of
the case, which will also involve assessments
and decision-making about ethical aspects. An
example of this would be the EU directive on
good clinical practice (GCP directive).
12
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1 For discussion of this question, see (inter al.) Jacob Dahl Rendtorff and Peter Kemp: ”Basic ethical principles in 
European bioethics and biolaw. Report to the European Commission, 2000”, Peter Kemp, Jacob Rendtorff and 
Niels Mattsson Johansen (eds.): ”Bioethics and biolaw”, Rhodos International Science and Art Publishers and 
Central for ethics and law, Copenhagen 2000.
2 The categorisation was originally produced for a report from the then Danish Ministry of Economic and Business
Affairs: ”Regeringens redegørelse til Folketinget om Etik og Genteknologi” [The Danish Government’s Report on
Ethics and Genetic Engineering as presented to the Danish Parliament] from 2001.
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International regulation will typically contain
obligations in relation to the content of national
legislation, but which permit a certain discre-
tion as to the implementation of, for example,
an international convention in national legisla-
tion. International regulation, however, does
not normally impose direct obligations on natio-
nal authorities.
EU regulation does place demands upon natio-
nal regulation (directives), but can also have an
immediate direct effect in relation to citizens
and businesses (regulations). 
Finally, EU regulation may impose requirements
on EU courts or EU decision-making processes
in so far as the decision-making competence is
not purely national. EU regulation of biotechno-
logy is content-based in relation to citizens and
businesses, as well as procedure-based, and,
for the latter, it involves both decision-making
processes related to EU courts and national
decision-making processes. 
National regulation applies directly to the ind-
ividual citizen or business, and can contain
standardisation of both content and procedure.
Ethical criteria do not come with a handy book
of answers in which we can look up whether a
method of treatment or a GMO-based crop is
permissible or not. But we can point to some
ethical considerations, which should form part
of any overall assessment prior to a ruling on
whether a method of treatment or a crop is
permissible. Additionally, it is important to
ensure the involvement of lay people in an
open process, so that ethical assessment is not
reserved for experts in a closed forum. Finally,
it should be ensured that the ethical assess-
ment is of specific applications of genetic eng-
ineering and not simply of more abstract ques-
tions of principle.
This points to procedural standardisation,
which, in relation to specific statutory rulings
on the use of genetic engineering, requires
that:
1. an ethical assessment is undertaken;
2. this is done on the basis of formulated 
ethical considerations; and
3. with the involvement of lay people in an 
open process.
2.2 Different actors
There are many actors involved, and these may
have a direct research or financial interest in
biotechnology, or be affected in a less direct
fashion, or have an interest based on a more
general viewpoint. These actors may have dif-
fering viewpoints and interests in respect of
research, implementation, financial exploita-
tion, administration, control, governance, etc.
of biotechnology.
2.2.1 Researchers, commercial 
actors and other affected 
parties
The researchers typically work with basic data
and generate information from them. They thus
generate expert knowledge, which is often of a
technical/scientific nature. One dilemma and
point of debate is to what extent researchers
can, should or will take an interest in communi-
cating and supplying information about ethical
issues in relation to their research.
Other sorts of researchers are interested in the
consequences of the utilisation of biotechnolo-
gy, etc. Examples of such researchers might be
ethics specialists, lawyers, sociologists, etc.
who, from information about biotechnology and
their own or others’ deliberations of the conse-
quences which the utilisation of different forms
of biotechnology will or may lead to, make
assessments of various kinds, including the sig-
nificance it will have medically and socially; the
changes of our standards and values which
may be at issue; the control measures and
options which will be required, etc., etc. While
ethics will relate the application of biotechnolo-
gy to various ethical principles (see above),
sociology will often take an interest in its more
concrete relevance to specific groups and for
society. Jurisprudence, based on pure scientific
research, the opportunities for utilisation, ethi-
cal principles and sociological considerations,
will be able to arrive at an idea of the extent to
which there is a need for democratic processes,
control, governance, etc. One might perhaps
say that these research areas constitute a sort
of metascience, which employs some of the
raw materials from the other sciences.
Commercial actors will be interested in finan-
cial exploitation of biotechnology. This applies,
for examples, to farmers, fishermen, food pro-
ducers, seed producers, etc.
Affected parties can be a number of different
groups. One of these will be patient groups,
who often press for research and utilisation.
Another will be environmental groups and other
interest groups, who often remain relatively cri-
tical of the utilisation of different forms of bio-
technology. Thus, among the affected parties,
there will be many heterogeneous and, to some
extent, conflicting interests.
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2.2.2 Decision-makers 
and administrators
Based on information they receive, decision-
makers, including politicians, will make the po-
litical judgement of the extent to which demo-
cratic processes, control, governance, etc.
should be implemented, and, based on their
political assessment, the form to be considered
desirable. In other words, they will be selecting
which tools to use from the toolbox. Decision-
makers can be, firstly, at the international level
(UN, WTO, European Commission, EU); second-
ly, at the national level (governments and parli-
aments); thirdly, related to different profes-
sions (medical associations and trade organisa-
tions); fourthly, individual clinics, hospitals,
businesses; and fifthly and lastly, the individual
person.
Administrators, including authorities, will
often develop the expert knowledge and trans-
late it into a concrete utility, e.g. in relation to
application, authorisation, policy and transpa-
rency. For administrators, there may be relati-
vely large scope for selecting tools in connec-
tion with preparation of legislation, the execu-
tion of decisions made through legislation, and
enforcing the legislation. When the regulation is
discretionary in nature, more precise guidance
is frequently sought as to which principles the
ethical assessment will be based on, and how
the more precise balancing of the ethical princi-
ples will be made.
2.2.3 The media and the 
general public/lay people
The media play a significant role in information
about research, ethical principles, concerns, etc.
The media often contribute constructively to
debate, but have a tendency to polarise stories
so that any balanced view is lost. For example,
future hopes can be given such an optimistic
slant that expectations are created which have
no basis in scientific fact. Or concerns may be
(over)emphasised. One of these does not pre-
clude the other, since the media do not need to
be consistent in their treatment of biotechnolo-
gy’s ethical dilemmas. In this, they are in con-
trast with regulation in the area, which must of
necessity be coherent and build on an internal-
ly consistent position. 
Finally, there is the question as to whether
there is not, quite besides the above-named
actors, a large and important group, viz. the
general public. In the general public there
can be said to be a wisdom which is of great
significance to ethical decision-making proces-
ses. The long-standing tradition in Scandinavia
for retaining the services of lay people in dif-
ferent organisations, councils and boards may
be regarded as a recognition of this wisdom.
The crux is that experts, including researchers,
administrators and politicians, each have their
own angle, but that these angles perhaps do
not include considerations which large groups
of the population wish to see dealt with. 
14
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3 Risk assessment -
between science and
values3
This section has the aim of shedding light on
the risks of biotechnology in the ”crossfield”
between risk and values. The section is based
on a more extensive report by Thomas Breck,
which is given in Appendix 2. This is interes-
ting, not least in the light of the fact that risk
assessment is a key concept in relation to
assessment of parts of EU regulation of bio-
technology - especially in the foods area -
while traditional scientific approaches are
changing to become more nuanced, with a hig-
her degree of value-based elements. While sci-
entific risk assessment has traditionally been
viewed as relatively unambiguous and therefore
a solid foundation for regulation, partly as
regards verification, partly as regards creating
a homogeneous legal position in the EU, ethical
assessments are considered to be more discre-
tionary, and this makes them more difficult to
validate and makes it easier for different legal
positions to arise in the EU. The difference bet-
ween the two approaches is, however, not
clear-cut. 
A glance at the last ten years’ debate on bio-
technology readily reveals that the risk aspect
occupies a prominent position. A large part of
the social conflicts played out around biotech-
nologies seemingly deal with these technologi-
es’ inherent potential for danger - their possible
risks. How will these technologies affect our
health and welfare, our social and cultural iden-
tity and the environment? And what precau-
tions should society take to minimise or alt-
ogether eliminate these risks? 
The word risk is often used to refer to unwan-
ted events in the real world, which can be des-
cribed in terms of their probability and their
consequences. Scientific risk assessments and
cost-benefit evaluations are tools employed by
technical and financial experts to describe the
risk in statistical and mechanical terms. The
objective is to provide a qualified basis for poli-
tical and administrative decisions, for example,
on whether a GMO can be authorised for mar-
keting or not.
Such scientific risk assessments have acquired
ever-greater significance for societal decisions
within modern biotechnology. At the same
time, however, criticism has been raised in the
public services of these assessments’ inadequa-
cy - criticism largely concerning the fact that
scientific risk assessments have a tendency to
treat risk as a neutral and objective dimension.
Risk is not just a question of science, but also
of values. 
Firstly, scientific risk assessment involves a
number of built-in choices of problems, met-
hods and descriptions. These choices can be
both well-founded and necessary, so that the
risk assessment taken as a whole can provide a
result that can be incorporated in a bureaucra-
tic context, but they are never value-free and
neutral. Secondly, there is a limit to the risk
assessment’s predication, that is to say the
relationship to reality on which it can meaning-
fully pronounce. Scientific risk assessment has
a tendency to include hard and quantifiable
aspects and conversely to preclude soft and
qualitative aspects of the risk concept.
3.1 Beyond the 
objective risk concept
In its most common sense, the concept of
”risk” alludes to a future unwanted event or
situation which one wants to avoid. A risk will
often contain an element of unpredictability. We
talk about the probability of one or other
unwanted event being large or small, and of
one risk being greater than another. This is the
concept of statistical risk which has gradually
15
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gained a foothold throughout society and which
can be immensely useful in many circumstances. 
This is how engineers, economists and statisti-
cians view risk; as concrete and tangible
unwanted events in the real world, which can
be described using numbers and probabilities
and thereby be made the object of calculations
and rational decisions. But precisely because
the statistical or objective concept of risk is so
widespread, it is important to be aware of its
limitations.
In the first place, the concept of statistical risk
is concerned with situations where the probabi-
lity and consequences are known and well defi-
ned. Either because there is substantial empiri-
cal experience or a well-defined theoretical
cause-effect relationship. When the conditions
allow, risk assessments can be a splendid
instrument on which to base decisions. But
many contemporary risks are not simple and
well defined. On the contrary, they are often
very complex and characterised by scientific
uncertainty as concerns both probability and
consequences. This is true, for example, in
areas involving hormone mimics and gene
modification.
Secondly, the concept of statistical risk presup-
poses that actors think and act rationally. The
reality, however, is that risk is influenced by
subjective, cultural and value-laden factors. For
example, the individual context means that the
risk of driving a car, smoking cigarettes or
making a parachute jump is perceived to be
more acceptable, since these are our own choi-
ces, under our own control. On the other hand,
chemicals in food, genetic modification and
similar risks imposed by other parties are seen
as less acceptable. Psychologists have scientifi-
cally proved that risks that are known, self-
selected, controllable and fair are seen funda-
mentally as more acceptable than the opposite
type. Added to this is the fact that risk is con-
strued differently by different cultures. For
example, Europe and the USA have different
views on the risk posed by GMOs to the environ-
ment. There is moreover a tendency for scienti-
fic experts to prefer risks that can be measured,
for authorities to prefer risks that can be regula-
ted etc. Fundamentally, this has something to do
with the fact that risk concerns unwanted
events, and that the question as to what is
unwanted, must, of necessity, be connected with
values. It is not least in areas where there is
great scientific uncertainty that value-based dif-
ferences will inevitably play a large role.
The third weakness of the concept of statistical
risk is that it has a distinct tendency to deal
only with the risk of mortality. The obvious
advantage of this is that all risks can then be
compared with each other across both individu-
al and cultural divides. Seen in isolation this is
all well and good, but one chooses then to dis-
regard some of the dimensions of the concept
of risk which are important for understanding
the conflicts surrounding risk that shape debate
in society. Aspects to do with scientific uncer-
tainty, with a failing confidence in science and
the authorities and with value-based and ethi-
cal questions.
In summary one can say that the technical/-
economic approach to risk, in spite of its indis-
putable merits, also presents blind spots and
dead ends, which make it less suited to under-
standing the many conflicts surrounding risk as
characterised by the media and the political
agenda in what is referred to as the risk society. 
To understand the risk society’s conflicts it is
necessary to adopt a broad, social concept of
risk, which includes risk as it is perceived and
construed by different individuals and cultures,
and which recognises that the conflict between
different interpretations and constructs of risks
has become a fundamental condition for policy-
making. A concept which does not reduce risk
to numbers and probabilities, but also sees it
as a question of social learning processes and
communication. In what one could also call the
new social risk reality, it is becoming increa-
singly difficult to refer to risks as something
real and well-defined, which can be communi-
cated in an effective and targeted fashion. It is
rather a question of contemporary risks occur-
ring, while we discuss them in a mediated pro-
cess, in which science still plays an important
role, but not as a clear and incontrovertible
authority. Rather as a store where different
social contractors acquire ammunition for their
arguments. Arguments which they present to
the arena constituted by the media, and where
different interpretations of facts and attributed
meanings fight over defining the risk and the-
reby also setting parameters for the political
solutions.
3.2 Biotechnology 
as a risk narrative
Modern biotechnology has from the outset been
associated with risk. As early as 1974 scientists
warned the rest of the scientific world that the
newly discovered recombinant DNA technique
poses a potential risk, for example, through
16
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genetically-modified pathogenic micro-orga-
nisms spreading outside of the laboratories. A
voluntary moratorium was agreed to, until rules
were introduced for the use of recombinant
DNA. This voluntary halt in the use of genetic
engineering is one example of reflexivity and
self-policing within the world of scientific rese-
arch, but it can also be seen as an example of
how scientific risk assessment has come to
completely dominate the regulation of genetic
engineering at the expense of ethical and wider
societal perspectives. Biotechnology has beco-
me institutionalised in the laws and regulations
of society as a potentially risky technology, but
the approval of GMOs is almost entirely based
on a scientific risk assessment informed by the
principle of ”if it’s not dangerous, it’s OK”.
The risk assessment has, however, limited
powers of predication. The process of hypothe-
tical questions and answers is structured as so-
called decision trees of the type ”if yes, go to
x” and if no, go to y”. In this way, the authoriti-
es’ expert advisers can ensure that all the ave-
nues are covered and the correct questions for
the authorisation procedure are asked. If none
of the questions on these lines produce a nega-
tive answer, an authorisation will be granted.
The risk assessment does not, however, take
account of knowledge that is lacking, i.e. situa-
tions we are unaware of or cannot envisage. In
this way, the need for a clear answer calls for
the risk assessment to deliver the whole ans-
wer, by which it has been obliged to provide a
more certain answer than it is in a position to.
In order for a risk assessment to be viable in a
bureaucratic, regulatory context, the complex
realities have to be reduced to something simp-
ler and more tangible. This does not mean that
risk assessments are useless, just that they
have limited validity.
It is here that the risk assessment loses its sta-
tus as a neutral instrument for measuring and
balancing probabilities and impacts, and beco-
mes itself a contributor to construing concep-
tions about the nature of the problem. By
accentuating the significance of certain factors
and playing down others, experts make a seri-
es of choices, which might be well-founded
enough, but are never value-free. It is crucial
for the validity of the risk assessment that
these choices and uncertainties are clarified.
When a risk assessment is used in a political,
regulatory context, however, the opposite often
occurs, namely that the choice and uncertainti-
es are played down in favour of an absolute
assertion about safety. The risk assessments
then come to appear as the absolute truth and
a guarantee against unwanted risk, which they
can never be. If unexpected and unforeseen
events occur all the same (as happened in the
BSE case), both the risk assessments, and the
scientific institutions and experts which perform
them, lose the confidence of the general public.
There is therefore a need for a change in socie-
ty’s use of scientific risk assessment which
allows for the scientific uncertainty of that risk
assessment. 
There are certainly two different ideas of what
a reflexive approach to risk assessment of this
nature might look like. One technical/scientific
and one democratic. The technical/scientific
approach revolves around the idea that science
will become better at assessing risks with
vanishingly small probability, but potentially
huge consequences in relation to, for example,
complex ecological systems. The intention is to
incorporate qualitative considerations into the
quantitative risk assessment. In this way, one
can, as it were, operationalise the use of the
precautionary principle, but keep it within a sci-
entific context. The alternative is a democratic
approach, which seeks to create greater open-
ness about the use of risk assessments - espe-
cially the uncertainties and choices associated
with them. Additionally, the aim is to include
citizens and other non-experts in the process
sufficiently early on so that the problem, which
the risk assessment is to shed light on, has not
already been finally formulated.
Accompanying this necessary discussion of the
capacity of risk assessments to predict reality,
there is, as stated, another discussion, which
deals with the values underlying the risk
assessment. The main assertion here is that
risk assessments are not, and can never be,
suited to encompass the value-related ques-
tions underlying the entire GMO debate. The
challenge therefore consists in breaking the
dominance of risk in the regulation of GMOs
and to make way for more value-based objec-
tions. The view is that the risk aspect may
indeed be important but is far from the most
interesting aspect of biotechnology. Indeed, the
technique raises a series of fundamental ethical
and societal questions. About respect for life;
about needs and welfare; about sustainability
and the need for a more holistic outlook on the
relationship between man and nature; and
about alternatives to centralisation and increa-
sed efficiency and productivity. Fundamentally,
it is a question of which values should charac-
terise future food production. There is a conflict
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between different world views and between
alternative views of humankind’s and society’s
problems and needs. What is immediately
apparent here is that the majority of GMOs that
have come to market so far are, at the value-
level, tightly bound up with the productivity
paradigm that has characterised industrialised
agriculture over the second half of the last cen-
tury. In other words, increased volumes and
productivity, a faster pace and cheaper pro-
ducts - improvements, which have occurred at
the expense of the environment, animal welfare
and social sustainability. Some believe that this
conflict will change with the second generation
of biotechnology products, which concentrate
precisely on qualitative improvements, but this
is far from given.
The conclusion is that even though biotechnolo-
gy raises questions about both values and risk,
it is symptomatic that public debate revolves
almost exclusively around risk. At the same
time, the dominance of risk in regulation is a
factor in delimiting the objections which can
legitimately be raised. Since risk is the only
recognised yardstick, one must either assert
the dangers of biotechnology - or put up with
being ignored. But this trivialises the debate on
both risk and values. It is important for the
reputation of biotechnology, for the public’s
confidence and for public debate to make way
for a new reflexivity, which must encompass
both the value of risk assessment and the valu-
es underlying risk assessment.
3.3 The communication of risk as 
a dialogue about uncertainty
Under the auspices of the FAO/WHO, work is
currently being undertaken to create internatio-
nal standards for risk analysis in the foods
area. In this connection a model has been set
out for what might be termed an ”archetypal
risk analysis” consisting of three steps: Risk
assessment, risk governance and risk commu-
nication. Risk assessment is the scientific part,
in which the problem is delineated and the risk
described in objective terms in terms of proba-
bility and impacts. Risk governance is the term
for the political part, where the societal bene-
fits and drawbacks are balanced against each
other and the safety levels are determined.
Risk communication is the term for the process
in which the result of the foregoing process is
communicated to citizens or consumers, in the
form of a threshold value, dietary advice,
hazard labelling and so on. This tripartition is
problematical, inasmuch as it presupposes a
sharp delineation between the scientifically
objective level (risk assessment) and the politi-
cal level, where values are introduced (risk
governance). As already stated, the reality is 
completely different.
Firstly, there is rarely one, unambiguous des-
cription of the risk. Scientific risk assessments
cannot be neutral, but depend on perspective
and are a matter of interpretation. Moreover,
they are based on a number of assumptions
and are thus representations of reality, but are
not reality itself. Many of the risks that typify
the risk society are characterised precisely by
our lack of knowledge about the relationship
between cause and effect - this is true of, for
example, BSE and genetic engineering. In
these areas, risk assessments become political,
and the ”scientificism” of matters political fol-
lows from a politicisation of matters scientific.
This contributes to blurring the sharp divide
between scientific risk assessments and politi-
cal risk governance.
Secondly, risk management has become frag-
mented. It is not a matter of offsetting costs
and benefits, as in a well-structured activity,
but often rather unstructured and decentralised
risk governance under the influence of many
different actors and interest groups who each
consider their balancing (read ‘their values’) to
be correct and appropriate in the context.
There is in the public sector a battle to define
and organise risk and its significance - risk
entrepreneurs propound and refute others’ risk
assertions.
Thirdly, risk communication is not a mechanical
work of translation, where the message, e.g. a
warning, a threshold value and so on, is trans-
ferred to the target group as efficiently as pos-
sible so that it can then act on the message.
Risk communication these days is more than
the communication of risk; it involves extensive
interpretation and debate about risk as pro-
pounded by different actors with demands for
specific political solutions and consequences,
since whoever controls the definition of risk,
also determines which solutions are relevant in
the context. Risk is construed, so to speak, by
the way in which it is communicated, and one
cannot distinguish between the real (objective)
risk and the perceived (subjective) risk, where
science and values are intermingled and where
scientific arguments can be difficult to differen-
tiate from politics and power. The arguments
are typically taken from the scientific domain,
but there is more to do than produce, set out
and interpret the results. This is not a case of a
18
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classic conflict between lay people and experts,
since there are both lay people and experts on
both sides of the conflict - and they are fighting
for legitimacy.
The conclusion for this new picture of risk - this
new social risk reality - is that there is a need
for new ways of addressing the issue of risk in
society and new ways of making decisions wit-
hin areas that are characterised by scientific
uncertainty, by conflicts and opposing interests.
There is a need for a new concept of risk com-
munication - one that dispenses with the notion
of effective communication. It is important to
enter the process as early as possible, and the
ideal must be to create parameters for a mea-
ningful public discussion of risk, by ensuring
that the relevant actors and interested parties
are involved in the formulation of problems and
strategies for solutions. This constitutes a
major challenge for the authorities that deal
with risk communication. The task will be to
ensure that the process is as fair, open and
transparent as possible, to ensure that all par-
ties are heard, that no important arguments
are ignored, etc. In other words the authorities
will become a sort of procedural consultant on
the risk issue. An important objective for
democratic and dialogue-oriented risk gover-
nance must be to open up the parameters for
legitimate objections that would also comprise
wider ethical and societal issues.
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• Regulation - overview
• Analysis of the regulatory picture
PART TWO
REGULATION OF BIOTECHNOLOGY
AT INTERNATIONAL AND NATIONAL LEVEL
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4 Regulation 
- overview
The following section outlines regulation in the
field of biotechnology. The aim is to provide an
overview of the current status of regulation in
order to localise the description of ”tools” wit-
hin a legislative framework. First, in Section 4,
we provide examples of international regulation
which reflect some of the ethical principles for
which consensus has been reached in prescri-
bing these as universal standards - at a global
level, and at the level of the Council of Europe
and at EU level. 
4.1 International regulation
Since the 1970s a number of attempts have
been made to formulate fundamental ethical
criteria for regulating biotechnology. In the fol-
lowing we will be discussing some of the main
criteria that have been established. The exam-
ples are concentrated around human health,
GMOs and foods, but we have also included
examples covering environmental issues and
human rights issues.
The following examples represent regulation
in which an attempt to incorporate ethical con-
cerns is in evidence. 
The UN’s Universal Declaration of Human
Rights and the European Convention for the
Protection of Human Rights and Fundamental
Freedoms exemplify the attempts to lay down
universal normative precepts for fundamental
ethical issues.
The Aarhus Convention on Access to
Information, Public Participation in Decision-
Making and Access to Justice in Environmental
Matters (the ”Aarhus Convention”) from 1988
affirmed ”the right to the environment”; not as
a material right, but as a number of judicial or
formal rights, including the right of access to
environmental information, public participation
in decisions on specific activities, and right of
complaint and of access to judicial proceedings
- for non-governmental organisations also.
The UNESCO Declaration of 1997 concerns the
human genome and human rights and pro-
claims, among other things, that the ”human
genome underlies the fundamental unity of all
members of the human family as well as the
recognition of their inherent dignity and diversi-
ty”. It goes on to assert that ”that dignity
makes it imperative not to reduce individuals to
their genetic characteristics and to respect their
uniqueness and diversity”. Finally the
Declaration prohibits financial gain from the
human genome in its natural state, and affirms
that the benefits of advances in the technologi-
es shall be made available to all, and that free-
dom of research is ”necessary for the progress
of knowledge”.
The Cartagena Protocol from 2000 concerns
biosafety and recalls the UN Convention on
Biodiversity from 1992. The Protocol prescribes
rules for international trade in living, genetical-
ly modified organisms (LMOs). The rules cover
risk assessment and risk governance for the
purpose of protecting human health. The
Protocol also contains rules on ”handling, trans-
port, packaging and identification”.
The Codex Alimentarius Commission was crea-
ted jointly by the FAO/WHO to develop global
food standards. Two committees prescribe gen-
eral guidelines on risk analysis and labelling of
genetically modified foods.
The mission of the WTO is to develop a multila-
teral system of trade, the aim of which is to
lower customs and trade barriers, and to abo-
lish discrimination in international trade. The
WTO has pledged to work for sustainable deve-
lopment and protection of the environment.
Article XX of the GATT agreement and the SPS
agreement cover all sanitary and phytosanitary
measures that might impact on trade between
nations and prescribes, for example, that mea-
sures may be introduced in contravention of
the principle of non-discrimination if these are
based on the precautionary principle. In cases
of scientific uncertainty the Member States are
permitted to adopt measures that must be
based on pertinent scientific information. Since
ethical concerns are difficult to document and
might be perceived as a paving the way for
ulterior national interests that might obstruct
the WTO’s mission to promote international
trade, it is difficult to take account of these
concerns. However, the so-called ”Shrimp-Turtle
Dispute” has eased the constraints on what
constitutes an ”exhaustible natural resource”.
The Trips Agreement on trade-related aspects
of intellectual property rights also contains a
provision that Member States may exclude
from patentability inventions contrary to ordre
public or morality or in order to protect human,
plant or animal life, or in order to avoid
impacts seriously prejudicial to the environ-
ment.
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4.2 The Council of Europe
The Convention on Human Rights and Bio-
medicine from 1997. The Convention prescribes
a number of minimum standards with which
each Member State must comply, while their
national legislation and practice may offer grea-
ter protection of the individual than that pre-
scribed by the Convention. The main purpose is
to protect individuals against exploitation ari-
sing out of treatment or research. The article
on purpose and object indicates that the ”parti-
es to this Convention shall protect the dignity
and identity of all human beings and guarantee
everyone, without discrimination, respect for
their integrity and other rights and fundamental
freedoms with regard to the application of bio-
logy and medicine”. The next article affirms
that ”the interests and welfare of the human
being shall prevail over the sole interest of
society or science”. The Convention also makes
provisions for equitable access to health care;
for professional standards; for consent and pro-
tection of persons unable to consent; for gen-
etic heritage and for scientific research. An
Explanatory Report is provided as a supplement
containing comments on the text of the
Convention. Furthermore, a number of proto-
cols have been ratified with a view to develo-
ping, in special fields, the principles contained
in the Convention, including a supplementary
protocol prohibiting reproductive cloning of
human beings. 
COMETH. In connection with the Council of
Europe’s work on bioethics, a provisional bure-
au known as COMETH (European Conference of
National Ethics Committees) has been appoin-
ted to promote cooperation and network forma-
tion among representatives of a number of
national bioethics committees. COMETH organi-
ses conferences for its affiliate committees on
general and/or topical issues in the field of bio-
ethics.
4.3 The EU:
Regulations drawn up under EU auspices inclu-
de a biotechnology patent directive, a system
for regulating approval of clinical trials on
medicinal products for human use, and regula-
tions to provide a framework for trials and
marketing of GMOs and novel foods. In addition
there is the EU Charter of Fundamental Human
Rights; EU-US Biotechnology Consultative
Forum, the European Commission’s policy
paper on life sciences and biotechnology, and
the work of the EU ethics group - EGE - which
reveal that efforts are now being made in the
EU to incorporate ethical concerns at a more
general and fundamental level. 
The Patent directive on protection of biotechno-
logical inventions from 1998 is designed to
ensure effective, legally harmonised protection
of patents and in so doing to serve to encoura-
ge innovation and promote investment in the
field of biotechnology. The directive contains
articles that prescribe restrictions based on
ethical concerns. According to these, inventions
may not be patented if their use in industry
would be against ordre public or morality.
Examples include processes for cloning human
beings; processes for modifying the germ line
genetic identity of human beings; use of
human embryos for industrial or commercial
purposes, and processes for modifying the gen-
etic identity of animals which are likely to
cause them suffering with no substantial medi-
cal benefits to man or animal, and also animals
resulting from such processes. Moreover, the
directive stipulates that the Commission’s
ethics group - EGE - is to assess all ethical
aspects of biotechnology.
4.3.1 The authorisation system for
medicinal products 
Council regulation on medicinal-
products 2309/93/EEC
This regulation lays down procedures for cen-
tralised authorisation of medicinal products in
the EU. It prescribes community procedures for
the authorisation and supervision of medicinal
products for human and veterinary use and
calls for the establishment of the EMEA.
According to the centralised procedure, marke-
ting applications are to be submitted to the
EMEA, a European agency for the evaluation of
medicinal products. The EMEA selects one of
the Member States as a rapporteur for the
application. The Member State’s competent
authority verifies the documentation submitted
in support of the application, while a scientific
committee under the EMEA assesses the appli-
cation itself. The EMEA grants a Community
marketing authorisation which applies in all EU
Member States (if the application is authori-
sed). 
All medicinal products derived from biotech-
nology, including those derived by genetic eng-
ineering must obtain an EU product authorisa-
tion in accordance with the provisions of the EU
regulation on medicinal products. National clini-
cal trials preceding an EU authorisation must
observe the rules laid down in the Declaration
of Helsinki, which means, among other things,
that they must be assessed by a scientific
ethics committee.
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Directive on medicinal products
for human use 2001/83/EEC
The directive on medicinal products for human
use comprises community code for how natio-
nal government authorisation of medicinal pro-
ducts is to be implemented. Once one Member
State has carried out an assessment of a medi-
cinal product and issued a marketing authorisa-
tion, the same product must be authorised
according to a more rapid and straightforward
procedure in the other Member States in which
the manufacturer wishes to market the pro-
duct. If a Member State disagrees with the
marketing authorisation granted by another
Member State the matter may be brought befo-
re the CPMP (Committee for Proprietary
Medicinal Products) attached to the EMEA.
Directive on clinical trials on
medicinal products for human use
2001/20/EC (GCP Directive)
This directive fleshes out the ethical principles
with specific instructions regarding the compo-
nents of a scientifically-based ethical assess-
ment. The purpose is to rationalise the proce-
dures involving documentation and administra-
tion required for conducting clinical trials, and
also to ensure patients of the same protection
in all EU Member States. This is what is often
referred to as a ”minimum directive” in that it
is only as prescriptive as the Member States
themselves deem necessary for the purposes of
protecting human subjects in clinical trials.
Before clinical trials may commence a number
of criteria must be satisfied, including the weig-
hing of predictable risks and drawbacks as
regards the therapeutic benefit for each trial
subject and or society as a whole; respect for
the trial subject’s right to physical and mental
integrity and right to personal privacy, and the
obtaining of informed consent and permission
to withdraw such consent. In Denmark, both
the scientific ethical committees and the Danish
Medicines Agency are each independently
responsible for authorising every application.
As a basis for conducting inspections, a
European database is to be established to
which the Member States’ competent authoriti-
es are to have access. Inspector visits to selec-
ted clinical trials are thus prescribed as a duty.
In this directive the EU has drawn attention to
ethical criteria.
Openness and co-determination 
The authorisation system is founded on the
requirement that the rules concerning expert
evaluation as set out in the directive on medici-
nal products are to be adhered to in both cen-
tralised and decentralised procedures. The rules
regarding good clinical practice promote self-
determination and autonomy for trial subjects
and thereby also underpin the principle of
openness and transparency. However, this
openness applies only to trial subjects specifi-
cally and not to the general public. In the field
of medicinal product evaluation no tradition
exists for publicising applications for marketing
authorisations with a view to conducting a
public consultation. This may be ascribed to
interests in protecting business secrets and
researcher rights. The GCP Directive now com-
prises rules regarding establishment of a
Community database with a view to publicising
extracts from applications and the evaluation
procedure, including, in particular the publici-
sing of adverse effects, though these data are
to be made available solely to the competent
authorities in the Member States. As such,
openness and transparency is ensured for none
other than the trial subjects and the competent
authorities.
4.3.2 EU authorisation system for 
GMOs, plants and foods 
A recurrent theme is that the Member States
are to employ risk assessment and the precau-
tionary principle when considering applications
for deliberate release and marketing authorisa-
tions. In connection with notification a public
consultation must be held, and consumer auto-
nomy must be assured by means of provisions
regarding labelling.
Directive on deliberate 
release 2001/18/EC
The directive on deliberate release lays down
the rules for environmental and health evalua-
tion of all genetically modified organisms that
are to be released into the environment. All
GMOs contained in products sold on the market
within the EU must therefore undergo environ-
mental assessment in pursuance of the princi-
ples in the EU directive on deliberate release.
Authorisations for deliberate release apply
throughout the EU. However, the environmental
provisions apply solely to LMOs. 
If a GMO is used in a food product or a medici-
nal product it must be authorised for use as
such in conformance with the Council regula-
tion on medicinal products (2309/93). In such
cases the environmental assessment will be an
integral component of the product authorisa-
tion, though still in accordance with the princi-
ples of the directive on deliberate release. All
the rules concerning authorisation of GMO-
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based products, including plants, foods and
medicinal products have undergone total har-
monisation. 
The regulation on novel foods 258/97 prescri-
bes requirements for authorisation of novel
foods, including GMO-based foods. The regula-
tion also lays down community code for autho-
risations and the general principles governing
labelling. These provisions ensure that consu-
mers have access to the necessary information
once the product has been placed on the market. 
Openness and co-determination 
The directive on deliberate release prescribes
that once an application has been received by
the competent authority, that authority must
publicise it with a view to conducting a public
consultation.
Procedure for authorisation of
GMO-based products
The actual procedures for authorisation of a
GMO-based product to be placed on the
European market are relatively consistent with
regard to plants, foods or medicinal products.
Assessment of the risks to human health and
the environment is performed by one of the
Member States - either the primary applicant
Member State or one appointed through a cen-
tralised procedure. The application is then for-
warded via the European Commission to the
other Member States who make their own
assessment and recommendations regarding
the application. This procedure forms the basis
for a vote on the application in the respective
official committees for the individual areas: The
committee for deliberate release, the standing
committees for foods and for medicinal pro-
ducts for human/veterinary use. If the official
committee rejects the application, this is then
passed on for a final ruling by the Council of
Ministers. If the application is approved, a mar-
keting authorisation is granted that applies
throughout the EU.
4.3.3 Other EU regulation, 
etc. The EU Charter of 
Fundamental Rights 
Proclaimed by the European Parliament, Council
and Commission in 2000, the Charter emphasi-
ses that the Union is founded on indivisible and
universal values of human dignity, freedom,
equality and solidarity; on the principles of
democracy and the rule of law. It contributes to
the preservation of these common values while
respecting the diversity of the cultures and tra-
ditions of the peoples of Europe, as well as the
national identities of the Member States and
the organisation of their public authorities. To
this end, it is necessary to strengthen the pro-
tection of fundamental rights in the light of
changes in society, social progress and scienti-
fic and technological developments by making
those rights more visible in a Charter. The pro-
hibitions cover issues such as eugenics practi-
ces, making the human body and its parts a
source of financial gain and the reproductive
cloning of human beings.
EU-US Biotechnology 
Consultative Forum
This body was appointed in 2000 by the then
US President, Bill Clinton, and the President of
the European Commission, Romano Prodi. The
Forum is made up of an independent group of
experts whose task it is to issue a joint assess-
ment of a range of complex problems arising in
connection with the application of modern bio-
technology in agriculture and the food industry.
The assessment report comprises recommenda-
tions concerning mandatory risk assessment, a
number of grants for independent risk rese-
arch, etc.
The European Commission’s communication,
Life Sciences and Biotechnology - a Strategy
for Europe from 2002 (COM 2002 27 final) (The
European Commission’s Policy Paper) proposes
a coherent strategy for biotechnology aimed at
formulating responsible, science-based and
people-centred policies on an ethical founda-
tion. The European Council of Ministers has
ratified this strategy. An action plan in support
of the strategy comprises an overview of
various action areas in which concrete initiati-
ves are to be implemented. The strategy
emphasises that the development and applica-
tion of life sciences and biotechnology must be
pursued with respect for the fundamental valu-
es recognised by the EU in the Charter of
Fundamental Rights. The strategy also stresses
that scientific and technological progress will
continue to raise new ethical and social ques-
tions, which should be tackled proactively on
the basis of an open and broad debate. The
action plan also indicates a number of action
areas with a view to strengthening the incorpo-
ration of ethical concerns, including information
and debate, the elaboration of ethical guideli-
nes/norms and a strengthening of the EGE.
EGE - The European Group on
Ethics in Science and New
Technologies 
EGE is an independent, pluralistic and interdis-
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ciplinary authority appointed to advise the
European Commission on ethical issues concer-
ning science and new technologies. It consists
of 12 members, all of whom have been appoin-
ted for their expertise and personal qualities,
and the group represents different disciplines,
including the health sciences and natural scien-
ces, ethics and theology, and law. Members are
appointed by the Commission for a term of four
years, which may be renewed once. The group
publishes Opinions, either on its own initiative
or at the request of the Commission. The
European Parliament and Council of Europe
may draw the Commission’s attention to ques-
tions they consider of major ethical importance.
For the purposes of preparing its Opinions, the
Group holds working meetings, invites experts
to take part, initiates studies and organises
public Round Tables. If an Opinion is not adop-
ted unanimously the Group must account for
any dissenting positions.
4.4 National regulation in the 
field of health
The following presents a kaleidoscopic view of
regulation in the human health area. The pur-
pose is to provide an overview of areas in
which broad agreement has been reached on
the need for regulation, as well as significant
differences between leading EU countries with
regard to the intensity and content of their
regulation. 
Medically assisted procreation is a classic
example of ”first generation” legislation in the
field of biotechnology relating to human health.
At the same time, a number of countries exhi-
bit relatively comprehensive regulation, though
with a relatively large degree of variation in the
method and intensity of regulation. The Council
of Europe’s Convention on Human Rights and
Biomedicine contains only few and modest pro-
visions regarding medically assisted procreation
(Art. 14). These focus on non-selection of sex
except where serious, hereditary gender-rela-
ted disease is to be avoided.
a) Consensus areas comprise: 
• access to medically assisted procreation 
restricted to married couples and co-habi-
tees;
• services in medically assisted procreation 
to be offered solely by clinics and/or per-
sons with a special licence to do so; 
• a licence or qualification to provide medi-
cally assisted procreation to be granted 
solely with regard for the principle of non-
commercialisation; and 
• gestational surrogacy contracts to be 
regarded as standard as unenforceable.
b) Areas of dissent comprise: 
• access to insemination and IVF by single 
women and lesbians;
• donation of eggs and fertilised eggs; the 
legal force of gestational surrogacy con
tracts; and 
• the method whereby the quality of such 
services may be assured. 
Genetic testing represents an area in which
regulation is less comprehensive. Regulation of
genetic testing is centred on protection against
predictive genetic tests ”imposed” by external
agents, especially employers and insurance
companies. This provision is set out in the
Council of Europe’s Convention on Human
Rights and Biomedicine, Art 12. The issue is
being deliberated at the EU level generally.
EGE, the European Group on Ethics, published
a report (Genetic Testing in the Workplace) on
the issue in 2000. In certain countries the pro-
visions in national regulation are more compre-
hensive. Norway, for example, has provisions
on genetic testing, and Denmark has in special
legislation from 1996 laid down provisions con-
cerning the collection and utilisation of health
information in connection with employment
with the purpose of protecting the right to pri-
vacy and integrity. 
Gene therapy is an area subject to limited
regulation. Where regulation does exist it is
usually centred on the difference between gene
therapy involving human somatic cells and
gene therapy on the human germ line. The
issue is referred to in Art. 13 of the Convention
on Human Rights and Biomedicine. In the EU
biotechnology patents directive, gene therapy
on the human germ line is given as an instance
in which patenting would be against ordre
public (Art 6 (2b)) National provisions concer-
ning, for example, prohibitions against gene
therapy on the human germ line also occur.
Biobanks represent one of the new areas that
have begun to attract regulatory interest. One
of the central issues concerns the extent to
which the use of biological materials for purpo-
ses other than that for which they were obtai-
ned (e.g. research) should be subject to
express consent (opt in) or whether it is suffici-
ent that no express dissent has been voiced
(opt out). In national regulation specific regula-
tions concerning biobanks are (as yet) relative-
ly rare, but the issues will often be covered
indirectly by general rules concerning data, etc.
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A recent, striking example of direct regulation
came with the advent of an act on biobanks in
Iceland in 2000. The purpose of this legislation
was to authorise the collection, storage, hand-
ling and utilisation of human biological speci-
mens in such a way that confidentiality is assu-
red. The issue is currently being discussed in a
large number of countries and further regula-
tion will thus conceivably appear on the agenda
in future.
Biomedical research represents a classic area
for regulatory efforts - albeit more in the natu-
re of soft law. The Declaration of Helsinki has
been heavily influential in the formulation of
international standards. The Convention on
Human Rights and Biomedicine contains
requirements regarding professional standards
(Art. 4); rules of consent (Art. 5 and others); a
general rule that scientific research shall be
carried out freely subject to the provisions of
the Convention and other legal provisions ensu-
ring the protection of the human being (Art.
15); and special conditions governing the pro-
tection of persons undergoing research (Art.
16). In national regulation we also often find
regulation designed to ensure scientifically-
based ethical assessment of biomedical rese-
arch projects. 
Research on embryos was one of the most con-
troversial issues to emerge in ”first generation”
regulation in the field of biotechnology.
Disagreement on the extent to which research
on embryos should be permissible is reflected
in an exceedingly vague general rule in the
Convention on Human Rights and Biomedicine,
which simply states that the law - where the
law sanctions such research - shall ensure
”adequate protection of the embryo” (Art. 18).
However, this rule is followed by an explicit sta-
tement, according to which ”the creation of
human embryos for research purposes is prohi-
bited.” At EU level also, we find in one notable
respect a provision regarding human embryos,
that is, the biotechnology patents directive,
which contains a specific prohibition against the
patenting of inventions involving the use of
human embryos for industrial or commercial
purposes (Art. 6 (2c)). In the national regula-
tion the legal position on embryonic research
varies considerably. 
Cloning, like medically assisted procreation,
bears on the most fundamental and sensitive of
considerations, in that it confronts the basic
premise of human conception. In its declaration
from 1997 UNESCO asserts that the reproducti-
ve cloning of the human being is to be regar-
ded as a practice in violation of human dignity.
In its supplementary protocol to the Convention
on Human Rights and Biomedicine, the Council
of Europe prohibits cloning, i.e. any interven-
tion that attempts to create a human being
that would be genetically identical with another
human being either living or deceased. At the
EU level the patents directive (on the legal pro-
tection of biological inventions) contains a pro-
hibition against the patenting of processes
aimed at human cloning for example. The
national regulation in a large number of coun-
tries contains a provision prohibiting cloning. 
Stem cell research represents the latest in a
series of regulations on biotechnology, and is
the object of much controversy. The Convention
on Human Rights and Biomedicine contains no
special provisions regarding human stem cell
research, as this was not on the agenda at the
time of its formulation. There are no EU directi-
ves or similar on research on stem cells, but
the issue has attracted widespread interest. In
May 2002 the EGE published a study on the
patenting of inventions related to human stem
cells. At the national level stem cell research is
generally not the object of specific regulation.
Of particular interest is the new legislation in
the UK that now authorises stem cell research
subject to fulfilment of a number of conditions.
Transgenic animals and xenotransplantation are
the object of special interest because they
represent a ”crossfield” between ethics concer-
ned with human health for both individual pati-
ents and in relation to the risk of epidemics,
and ethics in relation to animal welfare. Within
the EU the xenotransplantation issue is being
followed closely, but no directives or other pro-
visions exist for the area. 
4.5 The international picture and 
differences in the intensity of 
national regulatory activity
International provisions in the area of human
health are centred chiefly on four principles: 
a) non-commercialisation (regarding the sale 
of body parts and restrictions regarding 
patentability, etc.);
b) non-discrimination (e.g. non-selection of 
sex and in relation to genetic heredity);
c) autonomy (e.g. rules of consent and the 
right to know); and
d) the prohibition of reproductive cloning and
gene therapy on germ cells. 
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At the national level there is a much variation
in the extent to which any actual legislation is
applied nationally, and hence how binding the
obligations are on which regulation is based. If
we look at ”first generation” regulation of medi-
cally assisted procreation, etc. we can identify
the following models:
Laissez-faire means that there is no legislative
regulation or only very limited legislation or
other form of regulation. This model is found in
Italy for example, where it applies to the regu-
lation of medically assisted procreation and
other areas.
Liberal attitude means that legislative regula-
tion (hard law) exists only to a limited extent,
but that regulation is in operation through pro-
fessional standards or similar (soft law). This
model is found in the UK for example, where it
applies to medically assisted procreation (and
other aspects of health regulation).
Cautious legislative regulation means that rela-
tively well-developed regulation exists, also in
the form of hard law (in some cases in the
form of framework legislation). This model is
found in France and Scandinavia for example.
Prohibitive legislation means that full legislation
exists, and is focused principally on prohibitions
and punitive measures. This model is found in
Germany and Austria for example.
Thus we find that there are different reactions
in the different countries to what the relations-
hip between ”ethics and law” should consist of.
The advantages and drawbacks of the different
models are discussed in Chapter 8.
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5 Analysis of the
regulatory picture
In the following we analyse the state of the law
as regards ethics in regulation in terms of four
perspectives. Firstly, ”ethics where?” - that is,
in which areas regulation stipulates a duty to
incorporate or omit ethical principles (coverage)
and what scope this affords the individual
actors. Secondly, ”the ethics of what?”, in
which we consider the incorporation of ethics in
EU regulation in relation to medicinal products
and foods respectively in terms of research, cli-
nical trials, deliberate release and marketing.
Thirdly, the ”ethics of how?” - that is, by what
means ethics are operationalised in regulation.
Fourthly, ”which ethics?” - that is, differences in
incorporation and operationalisation of the four
ethical principles addressed by the present
report. Drawing on this analysis we consider in
what areas the incorporation of ethical princi-
ples is operationalised more extensively in
regulation, and in which areas further incorpo-
ration and operationalisation of ethical princi-
ples in regulation would seem to be merited.
5.1 ”Ethics where?” - coverage 
and scope of ethical principles
The international provisions in pursuance of
which ethical principles are incorporated and
operationalised in regulation relate chiefly to
two areas.
Firstly, human rights in relation to the human
health area. This applies especially to the UN’s
human rights convention, the Council of
Europe’s Convention on Human Rights and
Biomedicine; UNESCO’s universal declaration on
the human genome and human rights, the EU
Charter of Fundamental Rights in its reference
to, e.g. ”indivisible and universal values” and
the EU Directive on clinical trials of medicinal
products for human use. 
Secondly, the environment, biodiversity, biosa-
fety and so forth. This applies to the UN
Convention from 1992 concerning biological
diversity; the Cartagena Protocol on biosafety
and international trade in living, genetically
modified organisms, as well as the Aarhus
Convention on right of access to information
about the environment.
In these areas there is thus some degree of
obligation to incorporate ethical principles in
regulation at the national level. 
In other areas the scope for incorporating ethi-
cal principles, however, is more limited or non-
existent, even. This applies especially to GMOs
and foods. The foods standards laid down by
WHO/FAO in the Codex Alimentarius, like the
EU directives and regulations concerning the
marketing of genetically modified products and
so forth, contain provisions concerning risk
assessment, but leave no or little scope for
incorporating ethical concerns in the authorisa-
tion procedure itself. 
There are, nevertheless, certain ”openings” in
relation to the directive on deliberate release,
the directive on contained use, and the
Cartagena protocol on biosafety. Moreover, the
requirements regarding labelling and traceabili-
ty may be said to offer some scope for addres-
sing ethical concerns. Furthermore, the directi-
ve on medicinal products for human use con-
tains a provision in which although the authori-
sation procedure in connection with marketing
does not comprise ethical criteria per se, the
trials preceding marketing authorisation contain
ethical evaluations in accordance with the GCP
(good clinical practice) Directive. In this way a
link is forged between trials and marketing in
such a way that ethical criteria are integrated
at an earlier stage, which means that marke-
ting cannot proceed unless certain precondi-
tions regarding ethical evaluation have been
satisfied. National scope for incorporation of
ethical concerns is in this way limited when it
comes to what might be termed ”product regu-
lation under EU auspices”, since it is based on
total harmonisation, in which the rules offer no
possibility of ethical considerations - thus
making it a contravention of the directives to
incorporate them. 
The areas of national regulation are chiefly
confined to the health sector in the form of
medically assisted procreation, genetic testing
and gene therapy, research on human embryos,
biomedical research and so forth. Ethical evalu-
ations are often integral to authorisation proce-
dures, for example, when it comes to biomedi-
cal research projects. Besides these areas,
ethics may be included when restrictions are
imposed on ethical grounds for what may be
approved; as in, for example, a prohibition
against reproductive cloning; against employers’
requiring predictive genetic testing; against cer-
tain forms of medically assisted procreation
such as embryo donation, etc. The existence of
restrictions of this nature might be referred to
in terms of the establishment of a form of ”soci-
etal ethics” within a given nation, which are
subsequently reflected in national regulation. 
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n the absence of such regulation, the stage is
left to the other actors, that is, individual pro-
fessions, scientists, commercial operators and
so on. These actors may reach agreement on
certain norms for ethical evaluation. 
The scope for incorporating ethical evaluations
is in this way multifaceted: international ethical
principles are formulated to uphold human
rights and to maintain biodiversity and biosafe-
ty. Against that, a number of EU directives and
measures inhibit the incorporation of ethical
principles when it comes to GM products, inclu-
ding foods. At the national level ethical princi-
ples are centred on human health, while ethical
principles concerning the marketing of a num-
ber of GM products such as foods are thwarted
by the trend for total harmonisation of the EU
on this issue. In this way a number of areas
are left to other actors, in particular to ”pro-
fessional ethics”, ”corporate ethics” and ”indivi-
dualist ethics”. The issue is discussed in more
detail in Chapter 10.
5.2 Medicinal products, 
plants and foods - ethics
On pages 31 and 32 we have sought to devise a
table to indicate the manner in which interna-
tional requirements regarding medicinal pro-
ducts (for human use) and GMO-based foods
are implemented in respect of the criteria
governing research and marketing. In the main,
the rules aim to ensure consumer protection,
while the chief rationale underlying much of the
international regulation both as regards medici-
nal products and foods is to protect freedom of
trade in order thereby to lower the barriers
that prevent its free flow.
5.3 The ”ethics of how?” - 
different models for 
operation alisation
Whenever regulation involves the incorporation
of ethical principles, the manner in which these
are operationalised varies considerably. This
applies to the formulation of ethical provisions
as broad in scope, discretionary or precise, and
also applies to the manner in which ethics are
incorporated to regulate either content or 
process. 
5.3.1 Broad, discretionary 
or precise provisions 
International conventions are - almost by their
very nature - centred on broad, general provi-
sions, whereby only general ethical principles
are emphasised. References to the human
health area cite ”the precedence of human-
kind”, ”human dignity”, ”human integrity”, ”the
diversity of the human family”, ”respect for the
uniqueness and identity of individuals”, ”free-
dom, equality and solidarity”, and ”freedom of
research (and thought)”. In the area of the
environment and foods, reference is made to
”biodiversity”, ”biosafety” and ”the right to the
environment”, as well as ”sustainability”, ”the
precautionary principle” and so forth. 
These ethical principles set the parameters for
concrete, ethical evaluation of a given appro-
ach, application or the like, but owing to the
”elasticity” of the principles they are open to
differing interpretations. In a number of cases
therefore, a decisive factor will be the extent to
which the concerns embodied by the principles
are actually followed through - in other words
whether or not they are operationalised.
In national regulation also, we occasionally find
expansive statements of intent. This is the case
for French regulation, where dignity is a keyno-
te, and for Norway, which besides respect for
human worth, human rights and personal inte-
grity emphasises that the medicinal application
of biotechnology ”shall be for the common good
of a society that accommodates all”, and that
this must be based on ”the ethical norms
embodied in the cultural heritage of the
Western world”. Other countries take a more
direct approach, dispensing with general pre-
ambles in favour of explicit reference to funda-
mental ethical principles. In the UK for examp-
le, it is customary to open with a set of defini-
tions, while Danish and Swedish legislation for
example, typically begins by explaining what
area the act/statute covers.
When it comes to the details of how to actually
implement ethical principles, these have to be
translated into more explicit legal provisions.
The dilemma is that this will often involve a
”quantum leap” from major, sweeping princi-
ples on which everyone is agreed, to more pre-
cise rules, in which these principles must both
be balanced one against the other, and detailed
out in relation to discrete concerns. It is there-
fore small wonder that this localisation process
gives rise to major differences in the extent of
deliberations and attention to detail.
The dilemma is compounded by the fact that
the rule or provision itself may be discretio-
nary. This is the case, for example, with the
ordre public clauses in the biotechnology
patents directive and elsewhere, which merely
notes that a matter may be contrary to ordre
30
Ethical principles in european regulation of biotechnology | Linda Nielsen | Berit A. Faber | April 2002
031 Lilla rapport  03/09/02  14:19  Side 30
31
Ethical principles in european regulation of biotechnology | Linda Nielsen | Berit A. Faber | April 2002




Ethics: EU: Requirements that scien-
tists undertaking biomedical research
are to set out the ethical considera-
tions made during project planning,
and requirements that the EU evalua-
tion committee assess these conside-
rations.
Name:
EU Dir. 20/2001: Directive on clinical
trials of medicinal products. Minimum
directive.
Ethics: The GCP directive, Art. 6
(ethics committees) The remit of
ethics committees is detailed in GCP
Guidelines (currently under review)
(see Art. 8 of the Dir.).
NB! Exclusively rules regarding open-
ness for research subjects; no rules
on public information or consultations.
Name: 
Dir. 90/219 and Dir. 98/81 on contai-
ned use - large scale and greenhouse
trials (minimum directive).
Ethics: Dir. 98/81 Preamble conside-
ration regarding the requirement that
protection must be in place in order
to preserve and safeguard the envi-
ronment and human health.
Name: 
Directive on deliberate release 2001/18 
(total harmonisation directive)
Ethics: Preamble consideration
Ethics: EU: No general provisions for
incorporation of ethics.
National regulation: No tradition for
ethics in evaluations
Marketing Name:
Regulation on medicinal products
2309/93
(distinguishing between medicinal
products for human use and those for
veterinary use).
Ethics: Authorisation is conditional on
compliance with the procedure laid
down in the directive on medicinal
products (GCP).
Marketing authorisations may be
granted solely on the basis of GCP
and the latest standards of the
Declaration of Helsinki. 
Name:
Directive on deliberate release
2001/18 
(Plants, but not foods).
Ethics: 
Preamble consideration no. 9 concer-
ning the possibility of incorporating
ethical principles in evaluation of
applications for deliberate release and
marketing applications.
Article 9: Public consultation on the
application (openness and transparen-
cy surrounding the consultation).
Article 23: Protection clause
(health and environment).
Article 29: 
Consultation of EGE or similar ethics
committee.
NB! Exclusively rules regarding open-
ness for research subjects; no rules
on public information or consultations.
Name: 
Novel foods regulation (258/97).
Ethics:
No reference to ethics.
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Food labelling of novel foods.
Possibly EC Treaty Article 30,
(health/environment/ordre public).
Rules regarding labelling and traceabili-
ty.
No specific monitoring of adverse
effects (as regards human health).
Areas that contain principles related to ethical considerations (consumer protection in the form of labelling,
traceability, etc.).
Areas in which case law might sanction ethical considerations.
Areas that do not contain scope for incorporating ethics in evaluations.
In addition to these the EU directive on patents and the TRIPS agreement contain provisions regarding
ordre public in connection with the awarding of patents, which comprises both medicinal products and
plants/foods.
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UN - Cartagena Protocol. Introduces
precautionary principle. Informed
agreement reg. organisms in transit
(AIA - Advance Informed Agreement).
Obligatory labelling of GMOs. (Less
stringent rules concerning feed and
foods).
Article 23: Extended obligation to
involve the public in decision-making
processes concerning LMOs.
WTO: GATT Article XX, and SPS agre-
ement: Tendency to recognise envi-
ronmental concerns and exhaustible
natural resources as exceptions to the
general rule on prohibition of measu-
res presenting barriers to trade.
EU recommendations for regulations




Areas for which there are no direct provisions concerning ethics, but which include the possibility of 
ethical considerations via preambles or provisions regarding purpose.
Areas in which there are no ethical provisions, but which do not stand in the way of the application of
general principles.
Requirement regarding product infor-
mation (package leaflet to be compre-
hensible to lay people).
Urgent action (EC Treaty Article 30,
health/environment/ordre public).
Monitoring of adverse effects. 
Areas that impose requirements concerning ethics in evaluations.
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public and morality. In the Convention on
Human Rights and Biomedicine, the require-
ment that research on embryos be made the
object of ”adequate protection” is also an
example of an area in which the intention was
to provide discretionary leeway in order to
cater for differences in national perceptions. 
However, there are also instances in which
more precise provisions have been formulated
whereby ethical principles are operationalised
and acquire prescriptive content.
In such cases the principles 
tend especially to relate to
a) non-commercialisation
b) non-discrimination
c) prohibitions against human interventions 
regarded as unethical
d) protection of disadvantaged groups
e) risk assessment and labelling
5.3.2 Regulation of 
content versus process
Ethical concerns may be incorporated in legisla-
tive regulation in the form of content-based
standardisation, in which the rules indicate
expressly what is permissible or prohibited, or
in the form of procedure-based standardisation,
in which case-by-case evaluations comprise
ethical concerns. Content-based standardisation
is exhibited in the examples cited above, as
well as a large number of national regulations
in the area of human affairs (see Part 4). This
may be connected with the fact that this is an
area ordinarily regulated in the context of fami-
ly-based legislation and the like. However, sci-
entific research - and to some extent product
marketing - are not usually the object of con-
tent-based regulation. 
Procedure-based standardisation occurs in a
number of areas and in different formats, in
which the ethical aspect varies. A protocol for
authorisation involving the incorporation of
ethical concerns is the norm when it comes to
trials on human subjects. A typical sphere for
such protocols would be scientifically-based
ethical evaluation of biomedical research pro-
jects. In addition to which there is the regula-
tion of good clinical practice. 
Rules concerning public consultation, recourse
to raise objections, etc. are also found in the
foods area, yet in this context ethical principles
are not set out in explicit provisions. 
Furthermore, the rules concerning labelling and
traceability of GMO-based foods might be clas-
sed as a form of procedure-based standardisa-
tion that enables actuation of individualised
ethics. 
Finally, we find that a proportion of the pro-
cess-oriented regulation is geared to sustaining
a democratic process for tackling ethical dilem-
mas in biotechnology, including the appoint-
ment of ethical councils of various kinds. These
democratisation tools are described in more
detail in Chapter 6.
When it comes to precise, contextual regula-
tion, the greatest consistency is achieved in
operationalisation of ethical principles. The gre-
ater the discretionary element, the greater may
be the difference between operationalisation
and actuation. When ethical principles are
incorporated via procedural standardisation this
ensures scope and flexibility for ethical evalua-
tion, since an exhaustive tally is rarely made of
which ethical principles are to be incorporated -
often there will just be a requirement for an
ethical evaluation, or for the matter to be
brought before an ethics committee such as the
EGE. However, this may produce considerable
uncertainty as regards which elements are to
be incorporated in an ethical evaluation, and
how different ethical concerns are to be weig-
hed against each other. 
In this way we find that there is what might be
referred to as a ”quantum leap” from broad
principles or procedure-based standardisation
to ethical evaluation and decision-making.
5.4 Incorporation of the four 
ethical principles 
Economic and qualitative benefits
The Convention on Human Rights and Biome-
dicine and the UNESCO Declaration both stipu-
late that the interests and welfare of the human
being are to ”prevail over the sole interest of
society or science”. Also, when it comes to
medicinal products we find provisions for ensu-
ring that an evaluation is made of the ”thera-
peutic efficacy” to be derived from the trials
forming the basis for authorising the marketing
of a product. 
In the product area, including GM foods, the
provisions permit risk assessment in relation to
human health, but do not open up for ethical
evaluation of what economic and qualitative
benefits might be derived. 
Autonomy, dignity,
integrity and vulnerability
Human rights criteria and the regular incidence
of rules regarding ”informed consent” in a large
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number of areas may be taken as evidence of
incorporation of the ethical principle of autono-
my. The same applies - albeit more indirectly -
in rules concerning foods labelling in the sense
that such rules may be understood as an affir-
mation of the right of self-determination as
regards whether or not people wish to consume
GM foods. Dignity and integrity are classic
components in rules of the type that incorpora-
te ethical principles directly, and which more-
over often comprise more specific variants, e.g.
in relation to the right to privacy (personal data
protection), etc. The Convention on Human
Rights and Biomedicine contains a large num-
ber of rules for protecting especially vulnerable
groups of individuals. To these should be added
the rules comprised by national regulation for
the protection of children, including future gen-
erations, persons with senile dementia and
other vulnerable individuals. Finally, there are a
number of rules aimed at protecting the vulne-
rability of nature, including the environment,
biodiversity, etc. 
Just distribution of 
benefits and burdens
Unlike the first two principles, this ethical prin-
ciple has not achieved the same fixed, promi-
nent status in regulation on ethics in biotech-
nology. However, isolated occurrences do exist:
The UNESCO Declaration proclaims that
”advances in biology, genetics and medicine,
concerning the human genome, shall be made
available to all”. The Council of Europe’s
Convention on Human Rights and Biomedicine
refers to ”equitable access to health care”. The
preamble in the Norwegian Act on
Biotechnology is a national expression of this
commitment. However, the principle also has
importance as an ethical concern, that is, as
justification for approving GM foods, for
example, to the extent that this is to be regar-
ded as a means of helping to feed the world’s
population. However, this is not presented as
an explicit ethical principle underlying any
regulation. 
d. Openness and co-determination 
Openness and co-determination are ethical
principles that are increasingly finding general
consensus.
In the human health area the Council of
Europe’s Convention on Human Rights and
Biomedicine refers to the importance of promo-
ting public debate on this issue. The EU Charter
of Fundamental Rights also proclaims that the
Union is founded on ”the principles of democra-
cy and rule of law”. The European Commission’s
communication, Life Sciences and Biotech-
nology - A Strategy for Europe, emphasises the
importance of societal dialogue - proactive civic
responsibility - and monitoring, as well as sci-
entifically-based regulation. As cited earlier, the
Aarhus Convention on public access in environ-
mental matters proclaims a number of rights to
ensure openness and co-determination.
Similarly, the rules concerning marketing aut-
horisation for GMO-based foods lay down provi-
sions for public consultations. Moreover, all the
many ethics committees at the national and the
international level have the stated objective of
safeguarding openness, dialogue and co-deter-
mination. However, it is far from clear what the
concept of ”co-determination” actually embodi-
es. Public consultation and/or dialogue would
appear to be a given component, yet it is diffi-
cult to discern what actual influence the consul-
tative response and/or outcome of public dialo-
gue is intended to have. 
5.5 Summarising analysis - 
”gaps in Community 
regulation”
The overall regulatory picture that emerges is
delineated chiefly by four factors. 
Firstly: the differences in when ethical princi-
ples are promoted and when they are inhibited.
In the area of human rights and health interna-
tional provisions promote ethical concerns in
regulation to the extent that it is the duty of
each nation, profession and individual alike to
address ethical concerns - a duty which com-
prises the obligation of each nation to operatio-
nalise certain ethical principles in its regulation.
In the field of GMO-based foods we find that it
is chiefly international provisions that inhibit
the incorporation of ethical considerations,
since, in many instances, total harmonisation
prevails such that market interests and the
commitment to lowering trade barriers override
ethical concerns. 
Secondly, the juxtaposition of medicinal pro-
ducts and GM foods. In the area of human
rights and health the scope for incorporating
ethical principles in regulation would seem to
be considerable, especially with regard to clini-
cal trials involving human subjects, since this is
ensured by long-standing tradition. In the pro-
ducts area, including the foods area, however,
the scope for incorporating ethical considera-
tions would appear to be more restricted, not
least because the area is subject to total har-
monisation focused on scientific risk assess-
ment and only limited recourse to incorporating
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more generalised ethical principles and consi-
derations. The challenges in these two areas
therefore set them poles apart. In the last-
named area further consideration should be
given to whether it would indeed be desirable
and feasible to incorporate ethical principles to
a greater extent by means, for example, of
”gaps” in Community regulation, or, by calling
for regulatory amendments. 
Thirdly, the ”quantum leap” between general
ethical principles and the operationalisation
required for their actuation. This leap presents
problems and often causes agreement on fun-
damental ethical principles to give way to dis-
sent concerning the details of their interpreta-
tion, formulation and actuation.
Along the same lines, there is also the tenden-
cy to allow a number of procedural rules to
prevail. This has the advantage of flexibility,
but often becomes an impediment in that the
criteria for ethical evaluation are either inade-
quate or altogether absent. The challenge lies
in filling out this ”vacuum” with ethical princi-
ples that can serve as guidelines in concrete
ethical evaluations and decision-making 
processes.
Fourthly, that the ethical principles discussed in
the present report are not weighted equally in
the regulation that exists in the area. The
archetypal areas afforded protection are cen-
tred on autonomy, dignity, integrity, etc. in the
area of human rights and health, and to some
extent economic and qualitative benefits, as
well as broad-based principles of just distribu-
tion of benefits and burdens. However, these
have found their way into regulation in the field
of GMO products, including the foods area, only
by indirect means. Here the focus is on risk
assessment and on labelling such that ethics is
limited to ”isolated ethics”. This means that any
broader consideration of derivable benefit is not
made. The dimension that comprises ”proactive
civic responsibility”, debate and dialogue, open-
ness and co-determination would appear to
have increasing influence, though without any
clear perspective on how the right of co-deter-
mination is to be exercised. 
In order to facilitate discussion of how to
operationalise ethical principles in regulation it
would seem relevant to take a closer look at
the ”tools” at our disposal. These tools will the-
refore be the object of a more detailed discus-
sion and appraisal in Part Three.
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• Democratisation tools and debate models
• Regulatory instruments








The following presents some of the democrati-
sation tools that have been employed over the
last ten to fifteen years to establish openness
and debate. The main tools covered are: ethical
councils, ethics committees, scientific ethics
committees, selected debate models, selected
specialised ethics committees and joint bodies.
The ensuing discussion about the advantages
and drawbacks of these resources derives from
a combination of analysis work, interviews with
various people with experience and expertise in
the area, and our personal findings and
opinions.
6.1 Ethical councils 
(debate and advice)
There are now a range of different models for
ethical councils and committees in Europe.
France was the first country in the world to
establish an ethical committee; this was in
1983 (Comité Consultatif National d’Ethique
pour les sciences de la vie et de la santé). In
Denmark the Danish Council of Ethics was
established in 1989. Ethical councils were esta-
blished in Germany in 2001; in The Nether-
lands in 1999; in Sweden (Swedish National
Council on Medical Ethics (SMER)) in 1985; in
Norway in 1991; and in the UK in 1991, with
the assistance of private funds, an indepen-
dent, autonomous ethical council was establis-
hed, but not, however, based on legislation or
government decision. The UK government deci-
ded in 1998-99 to establish, instead of an
ethics council along the lines of the French or
Danish ones, two autonomous councils, each
devoted to their own specific field, namely
human genetics - The Human Genetics
Commission - and the agricultural and environ-
mental area - The Agriculture and Environment
Biotechnology Commission. Additionally, in
2000, the Food Standards Agency was set up,
with the remit of protecting public health from
risks that may arise in connection with food
consumption, and in other ways protecting con-
sumer interests in relation to foods, including
genetically modified foods.
6.1.1 Nomination and members
The number of members and their backgrounds
and representation vary somewhat. The French
ethics committee consists of a Chairman and
an Honorary President nominated by the
President, plus 39 members. 5 members repre-
sent the major religious denominations and are
nominated by the President. 19 members are
selected based on their qualifications and com-
petencies and their interest in ethical ques-
tions. 15 members work in scientific research.
There is therefore a high representation of spe-
cialist members, including specialists in ethics
and philosophy.
The Danish Council of Ethics consists of 17
members, made up of a mixture of specialists
and lay people. 8 members are nominated by
the Ministry of Health, 9 by the Danish
Parliament’s committee on the Council of
Ethics. The members are nominated for their
public commitment to the Council’s remit, and
they must not be a member of the Danish
Parliament, a local authority or a county coun-
cil. The act on the Danish Council of Ethics also
stipulates equal representation by men and
women. The Danish model for a council of
ethics is characterised by its large proportion of
lay representatives.
The German council of ethics consists of up to
25 members, covering the scientific disciplines
within the life sciences, medicine, theology,
philosophy, sociology and law, along with
experts in ecology and economic affairs.
Members of the UK Nuffield Council (ethics
council) are nominated by the council itself and
consist of various experts, of which around half
represent medical and scientific disciplines.
There are also experts in ethics and, for
example, an anthropologist and a broadcaster.
Members of the UK advisory ethics commission,
The Human Genetics Commission, are publicly
advertised for and selected by the Ministry of
Health. Most of the members are experts in
genetics, health, politics, law or bioethics, but
there are also others from, for example, trade
and industry - but no politicians.
The Swedish medical ethics council consists of
a chairman, 8 representatives of the political
parties and 11 specialist members.
In some countries members serve for a limited
period; e.g. membership of the Danish Council
of Ethics is limited to a maximum of 2 terms of
3 years, and in Germany members are appoin-
ted for 4 years.
Sometimes, there are also provisions for equal
representation of men and women, e.g. in the
Danish Council of Ethics.
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6.1.2 Objective
The French ethics committee is an independent
body linked to the ministries of research and
health. The committee has an exclusively advi-
sory function, and advises and prepares reports
initiated by questions from parliament, the
government, an institute of higher education, a
public institution or a recognised public rese-
arch foundation, as long as their main activity
is research, technological development, or the
promotion or protection of health. The commit-
tee can also take up matters proposed by
members of the committee itself or by others.
The Danish Council of Ethics has two main
functions - an advisory function for legislators
and the government and a dissemination and
debate-promoting function for the public. To a
great extent, the Danish Council of Ethics has
contributed to broadening the public debate by
arranging public consultations and debates
about ethical questions relating to the new
technologies within biomedicine. The Council
seeks to communicate ethical issues relating to
biotechnology and human health to non-specia-
lists. 
The German council of ethics is also indepen-
dent and sets its own agenda and modus
operandi. The aim is to discuss and arrive at an
ethical position on questions raised by new
developments in the life sciences, as well as
their consequences for the individual and for
society. A particular emphasis is given to links
with the public domain.
The UK Nuffield Council is also an independent,
autonomous ethical council, which, in the
absence of a national ethical committee as
such, has achieved a position as an important
player in the UK and international ethical deba-
te on the new biotechnologies and in the for-
mulation of UK policy in the area. The Council
sees it as its task to identify and define ethical
questions raised by the developments in biolo-
gical and medical research, with the aim of
responding to and anticipating public concern.
To a great extent, the Danish Ethical Council
has contributed to broadening the public deba-
te by arranging public consultations and deba-
tes about new technologies within biomedicine.
The council seeks to communicate ethical issu-
es relating to biotechnology and human health
to non-specialists. 
The UK Nuffield Council has published a large
number of reports with comprehensive scienti-
fic documentation and has, moreover, set up
meetings where ethical questions are examined
and reported on with the aim of promoting
public awareness and debate. From this basis,
new guidelines are often formulated in a num-
ber of areas.
The Swedish ethical council is appointed by the
government and has the task of shedding light
on medical ethical questions in relation to soci-
ety in general. The council provides guidance to
the government and parliament, which includes
assessing impacts on the individual and human
integrity in relation to medical research, diag-
nostics and treatment. It functions as a senior
advisory body, monitors developments in the
area and builds bridges between researchers
and decision-makers.
6.2 Scientific ethics 
committees (authorisations)
In a number of countries there is scientific
assessment of biomedical research projects
involving human subjects. In the following we
will be looking at the following countries in
more detail: The Netherlands (CCMO), Sweden
(Swedish National Council on Medical Ethics -
SMER), Norway (National Committee for
Medical Research Ethics - NEM) and Denmark
(the scientific ethics committee system - CVK
and others).
6.2.1 The committees’ 
composition
The Dutch committee consists of 11 members
and 8 experts (deputies). The committee has at
its disposal ethical, legal, medical and pharma-
cological expertise and expertise in nursing. As
well as its members, the committee also has
attached to it 10 experts with specialist compe-
tence in gene therapy, xenotherapy, immunolo-
gy, embryo and germ line research as well as
legal expertise. The committee is served by a
secretariat of 9 staff.
The Swedish committee consists of a chairman,
8 representatives of the political parties and 11
specialist members.
The Norwegian committee has at least 9 mem-
bers and, besides medical competence, has
members with competence in the relevant
research disciplines and specialist competence
in ethics and law. At least one of the medical
members has to have clinical competence and
the committee must also have competence in
genetics and psychology. At least two of the
committee’s members must be lay representa-
tives. The committee’s members are nominated
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by the Ministry of Ecclesiastical Affairs,
Education and Research following recommenda-
tions from the Norwegian Research Council.
They are initially appointed for a term of 3
years with the possibility of reappointment.
The Danish scientific ethics committees usually
have seven members, i.e. four lay people and
three specialists. The committees’ period of
operation follows the county council elections.
The members are nominated by the county
council. The lay members are generally county
council politicians. Their appointment takes
politics into account. The final nomination of
the specialists is also made by the county
council, but must previously have been appro-
ved by the three research forums of the
Universities of Copenhagen, Aarhus and
Odense and by the Danish Medical Research
Council. This procedure is to ensure that the
specialists have knowledge of research, e.g.
that they are active researchers.
6.2.2 Areas of responsibility
The Dutch central committee controls all medi-
cal research involving human subjects in The
Netherlands. The committee also supervises
the regional research ethics review committees,
of which there are several dozen in the country.
These local scientific ethics committees (METC)
must be approved, and there is a condition that
the committee fulfils a number of legal require-
ments as to its composition and articles of
association. The assessment of biomedical
research involving human subjects will be made
either by a local committee or by the central
committee, depending on the type of research
in question; e.g. gene therapy and xenotrans-
plantation trials, as well as certain projects
involving children, can only be assessed by the
central committee, which also advises on trials
involving the use of embryos and the human
germ line. The central committee (CCMO) also
acts as an appeals body.
The Swedish regional research ethics committe-
es assess research projects involving the use of
human subjects in biomedical trials. The activi-
ty of these committees is not regulated by law
and they are appointed on a voluntary basis. In
practice, biomedical research projects in
Sweden cannot be undertaken without approval
by a regional scientific ethics committee. These
are primarily based in hospitals and universities.
The Norwegian scientific ethics committee is an
independent body, which acts as a ”watchdog”,
information service and adviser at national
level. The committee’s job is to be a coordina-
ting and advisory body on research ethics for
the regional committees for medical research
ethics. Additionally, the committee is required
to inform researchers, administration and the
public about current and potential research
ethics issues in the field of medicine. In each of
the country’s 5 health regions, local committe-
es for medical research ethics (REK) have been
set up using guidelines laid down by the
Ministry of Ecclesiastical Affairs, Education and
Research, which also nominates the committe-
es’ members. The committees are required to
vet all biomedical research projects involving
human subjects.
The Danish scientific ethics committee system
is made up of regional, county-based scientific
ethics committees and a central scientific ethics
committee. From 1982, the system worked on
the basis of voluntary agreement, but since
1992 has been regulated by law. This means
that it is illegal to carry out a biomedical rese-
arch project without permission from a scienti-
fic ethics committee. The regional scientific
ethics committees assess medical trials invol-
ving human subjects, monitor approved trials
and participate in ethical debate in the region
concerning biomedical trials. The Central
Scientific Ethical Committee is an appeals body
for decisions made by the regional scientific
ethical committees, and this includes disagree-
ment within individual committees or between
several committees. The central committee has
no competence to issue binding guidelines to
the regional committees, but can recommend
that they treat certain types of projects using
particular guidelines, with the aim, among
other things, of ensuring consistent treatment
nationwide.
6.2.3 Assessment criteria
For the Swedish committee, it is laid down that
it must assess whether the project is scientifi-
cally beneficial to undertake, including whether
the anticipated benefits from the project out-
weigh any potential risks which the execution
of the project may have for the individual sub-
ject/patient. Furthermore, the committee has
to ensure that the subject is given sufficient
information about the implications of participa-
ting in the trial, and to ensure that informed
consent for participation is given.
In Danish legislation on the scientific ethical
committee system a number of conditions are
prescribed which need to be approved before a
trial can be undertaken. ”In its evaluation, the
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committee will take especial care that the risks
from the project are assessed, that subjects or
their guardians are fully informed about the
trial and have provided written consent, that
the subject understands that he/she can with-
draw from the trial at any time and that he/she
is apprised of the project’s finances.”
Moreover, the law also demands that emphasis
be given to scientific standards, in that the
committee has to assess whether the trial, in
its aims and methodology, meets high scientific
standards, and that there are adequate
grounds for carrying it out. 
This assessment has to be made because it is
unethical to include people in a trial which does
not have sufficiently high scientific standards. 
6.3 Other democratisation tools
6.3.1 Technology councils, 
including consensus 
conferences
The Danish Board of Technology and its proce-
dures will be used as a basis for analysis, since
it has worked with the consensus conference
model over a number of years.
The Danish Board of Technology has the job of
promoting awareness of technologies, their
potentials and consequences for people, society
and the environment; and this includes genera-
ting debate about technologies, assessing tech-
nologies and advising Parliament and the
government on technological issues. It is an
independent institution with a board of 10
members and a committee of 50. 
Consensus conferences have the aim of inclu-
ding citizens and their experiences in the tech-
nology assessment and are therefore conducted
as a dialogue between experts and citizens.
They normally stretch over 3 days and are
open to the public as concerns expert presenta-
tions and the consensus panel’s questions to
the experts. The role of the experts is to inform
a panel of citizens about the technology and its
implications. The civic panel then jointly drafts
a final document which contains a concluding
statement and position on the issue. The con-
sensus conference is managed by a planning
group, which advertises for and selects a group
of 10-15 citizens, summons suitable experts
and attends to conference promotion and publi-
city. On the first day of the conference the
experts have the floor, while the second day
provides the panel members with the opportu-
nity to put questions to the experts. After that,
the civic panel produces its final document,
which is presented and published on day three.
The model for consensus conferences consis-
ting of dialogue between citizens and experts
has been adopted in a number of other countri-
es. In the Europe region, consensus conferen-
ces have been held on the application of bio-
technology in France, Germany, the
Netherlands, Norway and the UK. The question
is whether it will eventually be possible to envi-
sage holding consensus conferences at the
European level, with a panel of citizens from
different countries.
6.3.2 Future panel
In connection with extending the dialogue with
politicians in the Danish parliament, the Danish
Board of Technology has established a future
panel of parliamentarians.
The future panel follows, over a number of
years, a field of technological development via
consultations and other events, and draws up
cross-party memoranda on the long-term politi-
cal potential and challenges in the field. 
The future panel is a new concept in
Denmark, which makes it difficult at present to
discuss its advantages and drawbacks. One
can, however, say that the intention is to ensu-
re that politicians have better opportunity for
direct dialogue with specialists about issues and
problems concerning the future use of techno-
logy.
6.3.3 Values workshop - Norway
This workshop is interesting because one of its
aims is to establish a dialogue with a specific
business sector about the ethics relating to the
future development of the business sector. One
example was Norway’s fisheries in 2020.
The aims included:
- providing a complete and well-founded 
value-based assessment of Norwegian 
fisheries;
- mapping out relevant values, so that 
explicit value choices can be made;
- trying out a new method with reference to
structuring ethical considerations as 
regards strategy choice; and
- engaging in debate on ethics in the fishe-
ries industry and in society.
The strategies included:
- establishing a network, including a 
working group from Norges Fiskarlag 
(fisheries union) and other institutions;
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- developing scenarios for the fisheries 
industry towards 2020, according to which
four scenarios provided the basis for clari-
fying ethical aspects of strategic decisions 
in the fisheries industry;
- developing an ethical matrix for the fishe-
ries industry, in which the ethical values 
are structured in relation to central ethical
principles and affected parties. The matrix 
is a diagram consisting of rows and 
columns with a checkbox, called a cell, at 
each intersection. There was then produ-
ced: an ethical matrix, in which the funda-
mental principles of fairness, dignity and 
welfare were specified for each affected 
party and then weighted to arrive at con-
crete values; an impacts matrix, in which 
specific options for action were evaluated; 
and finally, an evaluation matrix, in which 
numerical values indicate how far the 
impacts described in the action matrix will 
result in respect for the specification and 
weighting of the individual ethical values. 
On the basis of the evaluation matrix, a 
final estimation of the options for action is
made.
6.4 Cooperation between 
councils and boards
The distinguishing traits of biotechnologies, in
which different areas, actors and decision-
makers need to interact, make it expedient to
open up new avenues for cooperation.
The following gives examples of such coopera-
tion between councils and boards in Denmark.
a. Biosam
In Denmark over the last 5 years, closer coop-
eration and coordination has been implemented
between councils and boards working with
questions of bioethics as related to human
health, animals and biotechnology. This coope-
ration is centralised in BIOSAM, which is a joint
body of representatives from The Central
Scientific Ethical Committee, The Council of
Ethics, The Danish Board of Technology, The
Animal Ethics Council and The Animal
Experimentation Inspectorate, and which liaises
on ethical issues associated with biotechnology
research and the application of biotechnology,
including cloning and the genetic transforma-
tion of mammals. 
BIOSAM also contributes to making Parliament
and the public aware of new developments in
research in, and the application of, biotechnology.
The joint body must continually keep Parliament
and the public informed about its work and
take the initiative in making the ethical pro-
blems surrounding biotechnology the subject of
public debate. 
Furthermore, BIOSAM cooperates with the
interministerial taskforce for biotechnology and
ethics (BioTIK), which is responsible for imple-
menting a four-year action plan containing a
range of initiatives concerning biotechnology
and ethics. The BioTIK taskforce coordinates
statutory work in the field on the basis of
recommendations from an external BioTIK refe-
rence group, consisting of representatives from
councils and boards, non-governmental organi-
sations and researchers.
b. The Danish Council of Ethics
and the Animal Ethics Council
Two councils, the Danish Council of Ethics and
the Animal Ethics Council, have similarly, over
recent years, cooperated more closely, by hol-
ding joint information meetings. Additionally, a
particular joint focus has been directed at the
question of cloning. Thus, in 2000, the Danish
Council of Ethics published a discussion paper,
dealing principally with issues concerning tech-
nologies for tissue and organ propagation and
the future potential for the genetic manipula-
tion of humans and animals. 
c. The Danish Council of Ethics
and the scientific ethics commit-
tee system
In accordance with the act on the scientific
ethics committee system and the act on the
Danish Council of Ethics, the Central Scientific
Ethical Committee and the Danish Council of
Ethics are required jointly to address the more
fundamental ethical issues concerning biomedi-
cine. The Danish Council of Ethics’ task is to
advise the Minister for the Interior and Health,
Parliament’s committee on the Danish Council
of Ethics and the health authorities about ethi-
cal matters relating to new biomedical techno-
logy and human health. The Council is also
required to promote public debate about these
issues. Over the past decade or so, the coope-
ration has resulted in the holding of information
meetings in which representatives of the two
bodies have exchanged information about the
work. Furthermore, in recent years, there has
been closer cooperation between the Central
Scientific Ethical Committee and the Danish
Council of Ethics, which, among other things,
has given rise to joint events, in which both
bodies have planned and implemented the joint
initiatives. 
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d. Cooperation between the
Danish Central Scientific Ethical
Committee and the Danish
Medicines Agency
The Danish Medicines Agency and the commit-
tee system coordinated by the Danish Central 
Scientific Ethical Committee operate a parallel
procedure for authorisation of biomedical rese-
arch projects involving clinical trials of non-
approved medicinal products. The Danish
Medicines Agency grants the final permission
for such projects. According to this system of
bipartite decision-making competency, it is the
Danish Medicines Agency that makes the final
decision on any authorisation to commence tri-
als on medicinal products involving human sub-
jects. The Agency’s decisions must be made on
the basis of a recommendation from the com-
mittee system. Given that it is the committee
system that has the sole authority to conduct a
scientifically based ethical evaluation of a pro-
spective biomedical trial, the committee’s
recommendation is in effect binding on the
Medicines Agency as regards the scientific com-
ponent of ethical evaluations.
This bipartite decision-making mandate
entails liaison, and this takes the form of a
coordinating committee of representatives from
each of the two bodies. In recent years coope-
ration between the two bodies has been devo-
ted largely to the EU draft directive on good cli-
nical practice (GCP Directive), in which repre-
sentatives of both the Danish Medicines Agency
and the Danish Central Scientific Ethical
Committee participated in the EU talks. 
e. Collaboration on gene therapy
In 1999 there was a case in the County of
Aarhus concerning a research project involving
gene therapy on human subjects as part of a
study of the treatment of patients suffering
from hepatic cancer.
The ”Aarhus Case” revealed the need to esta-
blish interdisciplinary collaboration among the
authorities mandated to grant authorisations
for clinical trials involving gene therapy. Trials
of gene therapy involving human subjects
involve major environmental, epidemiological
and ethical aspects.
In response to this sequence of events a coor-
dinating committee was appointed by the
Danish Medicines Agency for the purpose of
promoting dialogue among the authorities
responsible for granting the various authorisa-
tions. The coordinating committee, made up of
representatives from the Danish National Board
of Health, the Danish Medicines Agency, the
Danish Central Scientific Ethical Committee, the
Danish Forest and Nature Agency and the
Danish Labour Inspectorate, attends to the aut-
horisation of human clinical trials involving
gene therapy.
6.5 Analysis and evaluation of 
democratisation instruments
6.5.1 Representation of experts 
and of lay people
Expert representation comprises groups of
expert delegates representing the disciplines
concerned, e.g. biotechnology, biomedicine,
philosophy and ethics, law, sociology and psy-
chology along with other disciplines as
required.
The advantages of having such representation
are that this provides a means of securing
comprehensive and well-founded academic
expertise for the advisory and decision-making
services rendered by the various committees.
In this context interdisciplinarity is crucial,
since under this concept the representatives of
different disciplines can meet and discuss ethi-
cal issues as a means of familiarising themsel-
ves with each other’s terminology, culture and
scientific traditions. This then serves to promo-
te mutual understanding among different scien-
tific domains.
It is essential that the concept of expert repre-
sentation is not defined too narrowly, and that
careful consideration is given to which experts
will be the most appropriate, especially with
regard to the need to include sociologists,
anthropologists, psychologists and other social
scientists.
The drawbacks of establishing forums compri-
sed exclusively of experts are that they may
have a tendency to become somewhat ”intro-
verted” in their choice of issues and mode of
discourse. Communication with the public and
decision-makers may be hampered by the fact
that many academics have no particular tradi-
tion for opening their debates up so as to make
them accessible and comprehensible to the
general public.
Lay representation involves delegations made
up as ”counterweights” to (academic) experts.
The involvement of lay people is already a
time-honoured component of the Danish judici-
al system, the purpose of which is to ensure
that the public’s sense of justice is reflected in
criminal procedure. In addition, the involve-
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ment of lay people occurs in public governance,
e.g. in central tax administration in Scandina-
via. In the consensus conference model the use
of lay people may be understood as drawing a
parallel with jury service in the administration
of justice. The experts are comparable with the
witnesses summoned before a court; the panel
with the jurors, who, after hearing the expert
testimonies, withdraw to formulate their collec-
tive response to the conference issues, infor-
med by the presentations of the experts and
their own common sense.
The advantages of drawing on the services of
lay people are, among things, that they have a
confidence-building function, whereby the link
with general public opinion and common sense
may be sustained. Lay people thus serve to
contribute an element of ”wisdom”, which ensu-
res that account is taken of the opinions and
convictions that exist as implicit tenets in the
values embraced by a population. This should
also be considered in the light of the fact that
lay people are perfectly capable of acquiring
objective and valid insights and that scientific
experts are just as susceptible as lay people to
subjectivity and personal factors. Moreover, the
involvement of lay people serves a democratic
function in that it exercises the principle of
autonomy and counteracts the formation of
unintended power bases. This serves to esta-
blish what might be termed a ”bottom-up” ele-
ment in decision-making processes, just as it
ensures dialogue on the issues that the public
finds to be important, and ensures that the
concerns deliberated are communicated to the
public in a way that is comprehensible to the
”man on the street”, and which thereby contri-
butes to social and democratic learning proces-
ses. The subjective and personal factors
brought into play by lay delegates will thus be
incorporated in consultations on the issues that
present themselves for discussion.
Denmark maintains a large body of lay people
in its ethics committees - according to a model
in line with its long-standing tradition for retai-
ning the services of lay people in the judicial
system, in connection with jury service in
appeals courts, for example. The findings of
consensus conferences have been that ordina-
ry, motivated citizens are capable of acquiring
and analysing complex scientific information,
and of drawing their own, independent conclu-
sions. The ”worldly wisdom” possessed by lay
people serves to complement the more abstract
and generalising insights of academic experts
and thereby contributes to a more balanced
foundation for decision-making than if all deci-
sions were made solely by such experts.
The drawbacks of retaining the services of lay
people include the risk that they may become
”over-qualified” in connection with their invol-
vement and representative services to expert
bodies. A failure to take special account of the
fact that the role of lay people is precisely to
provide the originally-intended safeguards and
to approach the issues from new angles might
mean that the values and culture of the acade-
mic experts might come to dominate the agen-
da such that the lay element is at risk of being
”held hostage” by expert opinion. It should the-
refore be ensured that the views held by lay
representatives are allowed to evolve freely,
and that ”down-to-earth” opinions are not com-
promised. Further problems may arise if exten-
sive lay participation displaces the volume of
experts deemed necessary without excessively
swelling the ranks of the organisation.
Political participation in debate-generating
activities will often be useful; the problem
being that politicians tend to be reluctant to
get involved at an early stage in issues that
may be regarded as ”dangerous” or ”awkward”
to take a public stance on. In relation to ethics
committees, one purpose of which is to serve
as an advisory function, it is doubtful whether
political participation would be of value.
The advantages are that this ensures a ”direct
line” to the political domain, which in turn
ensures that the advisory element dominates,
and that the political domain becomes accusto-
med to discussing difficult ethical issues in gre-
ater depth.
The drawbacks may be that politicians run the
risk of backing a given opinion prematurely,
which again may pose further problems. The
risk is also that the political level engages too
early in the process, when it may be more
helpful if the debate can proceed in the absen-
ce of political interests.
One conclusion on the views presented here
might be that it is vital to ensure broad inter-
disciplinary expert representation - possibly
complemented by a panel of academic advisers
who may be consulted on specific matters - but
that there may equally be a need to ensure lay
representation, both in the democratisation
instruments designed to generate debate, and
in ethics committees - whether these serve an
advisory or controlling function. This ensures
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an open, transparent system, as well as a
counterweight to prevent medico-professional
and research-based interests from dominating
in relation to the mechanisms for protection
that may be deemed equally important. At the
same time this promotes valuable dialogue bet-
ween experts and lay people. In this context it
is important that lay people are provided with
sufficient, readily comprehensible information
such that they may render their services on a
sufficiently well-informed basis, being apprised
of the technical data.
The retention of lay services is often endorsed
in relation to debate models proper, which refer
to public debate in various forums, etc.
However, it is important that the lay contingent
and generalised debate are also employed in
relation to scientific ethical committee systems
in which actual authorisation of biomedical
research projects is effected, since these com-
mittees do not necessarily consider broader
ethical implications involving general societal
concerns and regard for future generations.
Such aspects may play an important role in
connection with deliberations on research pro-
jects seeking to employ technologies such as
xenotransplantation, stem cell research and
cloning of human cells. Deliberations on the
broader ethical implications of such projects
should therefore be ensured by retaining the
services of lay people in scientific ethical com-
mittee systems and by incorporation of the
debate models proper.
The question of the term in which lay people
should serve has also been debated. The fact
that it takes time for lay people to familiarise
themselves with complex issues speaks in
favour of an extended period of service. In con-
trast, the fact that it may be necessary at
times to ”inject” fresh opinions and new partici-
pants into the debate speaks in favour of a rat-
her more limited period of service. The latter
argument would seem to be the more persuasive.
6.5.2 The purpose and 
role of the committees
It is often emphasised that is of the utmost
importance for ethics committees to be inde-
pendent. Only in this way can they meet the
need for information and debate in a way that
comprises an objective stance on current regu-
lation and prevailing opinion, even when this is
at odds with the position held by government
and parliament for example. The UK Nuffield
Council has even gone so far as to stress that
independence from national government is
important in the light of an evident lack of
public confidence in government-appointed
advisory bodies. It may therefore be preferable
to establish independent bodies of this nature -
ideally at the national level - and to furnish
them with sufficient financial resources to allow
them to act in an advisory and debate-promo-
ting capacity. While some countries have a
single, centralised ethics committee and sub-
committees to attend to the more detailed par-
ticulars, other countries primarily rely on a
number of dedicated committees. Similarly,
commissions may be permanent or provisional,
mandated to generate debate, to advise, aut-
horise or regulate, and assigned a more or less
explicit remit.
One essential aspect is to avoid any dispute
over authority among the various bodies
appointed, and prevent overlap and the dupli-
cation of effort this might give rise to. In this
respect it is important to establish actively coo-
perating bodies. This need also emerges from
the fact that many of the ethical issues addres-
sed touch on multiple concerns that may need
to be addressed by separate committees. The
need for interdisciplinarity and cooperation is
therefore pronounced.
The difference between the desire to achieve
consensus or not is based on a weighing of
advantages and drawbacks.
The advantages of consensus would appear to
be that the greater the level of agreement pre-
sented by a given ethics committee, the grea-
ter will be its prospects of bringing influence to
bear on the regulators.
The drawbacks are that such a committee will
thereby forfeit much of its impetus, since con-
troversial issues and/or principles are usually
the very aspects that make consensus difficult
to achieve. It may therefore be helpful to fur-
nish the decision-makers with detailed informa-
tion as to where any dispute might arise, and
which ethical principles may be assessed and
weighed differently such that the decision-
makers will have the best possible basis of
information at their disposal to assist their deli-
berations.
There is also a need to establish cooperation
among the various administrative units assig-
ned to address ethical concerns - partly in the
form of experience exchange, partly with the
aim of ensuring that there is minimal inconsis-
tency within a single area and between one
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area and the next. The same issue may arise
among regional, local hospital-based authorisa-
tion bodies, for example, meaning that practi-
ces may vary in different national regions. This
coherency would seem appropriate in the light
of the fact that local variation should be
acknowledged, whereas in terms of equality
this may appear less reasonable.
6.5.3 Criteria for ethical 
evaluation
One of the difficult questions concerns which
criteria should determine whether an authorisa-
tion is granted or rejected.
The ethical principle of economic and qualitati-
ve benefit is occasionally comprised by precon-
ditions dictating the balancing of the risks
against the benefits of carrying out a given bio-
medical research project involving human sub-
jects. In addition, we occasionally find a requi-
rement that there must be justification for car-
rying out a project. However, the problem may
be that the decision-making process and the
decision-making forum concerned may not be
geared to or possess the resources to make a
broad and more nuanced ethical evaluation,
confining itself instead to a more narrow, scien-
tifically based ethical angle of approach. In the
debate models these ethical principles will often
be incorporated, despite the fact that they may
be challenging to deal with, since it can be
inordinately difficult to predict economic and
qualitative benefits balanced against any longer
term risks.
Autonomy, dignity, integrity and vulnerability
are assured in scientifically-based ethical aut-
horisation systems in the shape of the require-
ment concerning informed consent. However, it
is doubtful whether the principles of dignity,
integrity and vulnerability will actually be sub-
jected to sufficiently incisive, nuanced and pre-
dictive considerations in an authorisation system.
Just distribution of benefits and burdens are
not incorporated in the authorisation system,
save for the requirement that there must be
justification for carrying out a trial. However,
there is often reason to question whether those
research projects that do go ahead actually
take sufficient account of the needs assessment
that this ethical principle represents. In the
debate models, this principle can readily be
addressed - which it often is, but here too it
will often be difficult to document and analyse
its use in any detail.
Co-determination and openness form the basis
for the debate models in the various formats
discussed in the foregoing, and it is encoura-
ging to find that these principles are becoming
more widespread all the time and have now
also been identified with great emphasis by the
EU in the form of a drive for ”proactive civic
responsibility”. However, in the authorisation
system the principle of co-determination and
openness in decision-making is far from always
observed, among other things because the
issue of intellectual property rights may conflict
with the provision of more extensive informa-
tion. Greater openness could presumably be
achieved without producing any conflict with
patent rights and so forth, which would be
desirable in the case of any applications that
raise more general ethical issues.
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7 Regulatory 
instruments
In the following we outline the functions of
regulation and introduce various forms of regu-
latory instruments. The advantages and draw-
backs of the various regulatory instruments will
subsequently be analysed and evaluated.
7.1 Regulatory function
Legislation has three primary functions, that is:
normative, protective and regulatory:
7.1.1 The normative function
International instruments will to a great extent
often be normative in nature in the interests of
achieving consensus. Examples of this may be
found in the UNESCO Declaration, the Council
of Europe’s Convention on Human Rights and
Biomedicine and the EU Charter of
Fundamental Rights (see Section 4 above). Art.
6 of the ordre public clause in the EU patents
directive also contains a provision that can be
characterised as normative. In addition we find
that national traditions in some countries con-
tain examples of provisions with a normative
quality. The normative component of legislation
entails that certain values and interests are
emphasised as worthy of protection. Such valu-
es and interests might include human dignity,
protection against genetic discrimination, prohi-
bitions against germ line interventions, cloning,
hybridisation and research involving embryos
(after a certain timespan). This function of the
legislation is based on a vision that laws may
be educational, a means of exercising ethical
principles. 
7.1.2 The protective function
This function of legislation balances protected
values against other interests, and prescribes
sanctions for abuse, while it seeks to minimise
risk factors for patients and other persons
affected by biotechnology and its applications.
Examples include the protection of children
born as a result of medically assisted procrea-
tion and persons in a vulnerable position such
as those applying for a position of employment
or for insurance cover, etc. This may produce
legislation to ensure that people cannot be
legally required to undergo genetic testing, etc.
in cases where they are applying for a particu-
lar job, insurance, a pension or the like. In this
way their ”right not to know” about their gen-
etic heritage may be protected. Legislative pro-
tection may be necessary because informed
consent does not offer adequate protection in
situations where there is inequality in status. It
is therefore not a question of saying yes or no
to genetic testing, but of saying yes or no to a
given job or a given insurance policy.
Another example is the function of protecting
future generations. This concern is to be regar-
ded as of such importance that it must neces-
sarily be ensured by legislative means, among
other things because there can be no certainty
that this concern will be observed by those
immediately affected. Besides the physical
environment the regard for future generations
can also be observed by safeguarding the cul-
tural environment, social interactions, etc.
Finally, protection in the form of legislation may
be appropriate for purposes of risk minimisa-
tion, as exemplified by the precautionary prin-
ciple.
Many of the areas in which the protection con-
cern is an issue will be those areas in which
informed consent does not provide adequate
protection, either because those affected are
unable to give such consent, or because depen-
dencies, positions of power and the like effecti-
vely mean that informed consent does not
afford adequate protection.
7.1.3 The technical function
The technical function can provide clarity and a
reliable method of dealing with controversial
areas in biotechnology. The legal status of
much of what goes on in practice in relation to
biotechnology may be unclear in the absence of
explicit rules. Regulation can ensure that those
involved know what is acceptable or not accep-
table so that they can perform their duties and
make their decisions in compliance with this. 
One example is regulation in relation to scien-
tists performing research involving embryos,
and firms working on xenotransplantation, in
which those affected by regulation of what is
permissible/ not permissible are provided with
a legally binding framework such that they do
not need to assume any personal responsibility
for whether a given research project is to be
regarded as ethically defensible. Moreover,
rules concerning confidentiality and duty of
non-disclosure in relation to genetic information
obtained by doctors may also be seen in this
context. Furthermore, legislation can guarantee
special rights, for example, patient rights, the
doctor’s right of refusal, the patient’s right of
refusal and so forth.
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Overall, one conclusion might be that the tech-
nical function is there to prescribe definitive
rules for what is ethically acceptable/unaccep-
table, and to define precisely which rights and
obligations must be observed by all parties
concerned - in their mutual dealings and in
relation to society.
7.2 Different types of regulatory 
instruments
Surveying biolaw across Europe, examples of
different legislative instruments would include
those listed below.
Framework legislation enables the establish-
ment of special forums with the right and duty
to undertake evaluation of ethical implications
of selected fields in biotechnology. Examples
include the appointment of ethical councils,
committees for scientific ethical evaluation,
bodies imbued with the right and duty to award
licences under certain terms, authorisation pro-
cedures and so forth. This form of instrument
ensures, through parliamentary channels, that
a domain may be established in which ethical
debate can thrive.
Informed consent has come to represent one of
the keystones of health legislation in recent
years. Informed consent is consequently a pre-
condition for treatment, medically assisted pro-
creation, participation in clinical trials, trans-
plantation, etc. Rules concerning informed con-
sent serve to guarantee autonomy. Obviously,
special problems may arise in relation to chil-
dren and other persons unable to give informed
consent. 
Directives, authorisation requirements or the
like permit the formulation of provisions that
certain treatments, research activities, etc.
may be carried out only on condition that a
licence, authorisation, permit or similar has
been obtained. In addition to which there are
the directives prohibiting certain methods,
objectives, etc.
Rights may be granted by legislation. One
example would be patent protection, according
to which a patent holder is accorded the sole
right for twenty years to industrial use of a
patented invention. Another example would be
the right to retain frozen sperm, eggs or
embryos following the death of the donor, or
the right of relatives to consent to or not give
consent to organ donation. A third example
would be revocation of donor anonymity such
that a child produced by donation is accorded
the right to be informed of the donor’s identity.
Prohibition and sanction are familiar forms of
regulation. Examples of prohibition and punitive
provisions would include bans on cloning, on
gene therapy on germ line cells, on ”chimeras”,
etc. and on retaining embryos in vivo for rese-
arch purposes for more than fourteen days.
Other examples would include prohibitions
against requiring genetic testing in connection
with employment or insurance.
Moratoriums are a form of regulation that have
acquired status in relation to biotechnology.
Moratoriums suspend activity, giving pause for
thought so that the actors involved can find
their ”ethical feet”, and avoid a situation in
which it becomes impossible to impose mea-
ningful restrictions because a given practice
has become commonplace before it has under-
gone ethical evaluation. At the same time the
burden of evidence is, as it were, shifted, in
the sense that those seeking to introduce new
practices are obliged to argue their case.
Professional standards can take the form of soft
law, that is, guidelines that are not binding in
an official, legal sense. Recommended guideli-
nes of this nature may be laid down by a scien-
tific association, and any sanctions for non-
compliance with the guidelines may vary. A
notable example is the World Medical
Association’s Declaration of Helsinki on medical
research involving human subjects. 
Case law, consisting of the written opinions of
judges giving the verdict in a particular case, is
the standard form of regulation in a number of
common-law countries such as Great Britain.
According to this system, the link between
ethics and law is created by case-by-case ver-
dicts brought before the judiciary. From the
specifics of case law, more general ethical prin-
ciples with legal force can sometimes be elici-
ted.
Regulation of education and research are
important models for ensuring the operationali-
sation of ethical principles. This can be a
means of creating scope and tradition for incor-
porating ethical reflections and considerations
at the earliest possible stage in any procee-
dings. The need to include bioethics as a sub-
ject in education comprises both ethical issues
associated with a particular field of research or
practice, and more general ethical issues. The
connection between natural sciences/health sci-
ences, ethics/philosophy and law/social scien-
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ces means that there is a need for an interdis-
ciplinary approach to the issues raised by the
new biotechnologies. This can promote direct
dialogue and thereby mutual inspiration. It is
essential that students be introduced to bioet-
hical issues early on in their studies. At a later
stage, bioethical topics can then be explored in
greater depth as required, especially in relation
to more narrowly defined, subject-specific issu-
es and concerns regarding research ethics. 
One noteworthy example of a drive to ally
research interests with ethics, environment and
safety is found in article 1 of the Norwegian act
on genetic engineering, which lays down three
general requirements regarding the production
and use of genetic engineering, and regarding
applied or commercial research: It must 1) be
ethical and socially defensible, 2) be in confor-
mance with the principle of sustainable deve-
lopment, 3) cause no damage to health or the
environment. 
Besides the need to create a common platform
for addressing ethical issues, it is important to
create a well-founded basis for discussion and
knowledge exchange among students and wor-
king scientists, so that they can participate in
and influence qualified public debate about the
ethical questions linked to these issues. Studies
(made in Denmark by Peter Sandøe and Gitte
Meyer4) have shown that scientists and the
public not talking the same language repre-
sents a serious barrier to dialogue - there are
different conceptual interpretations, in that, for
example, scientists use a broad concept of util-
ity and a narrow concept of risk, while the con-
cerns of the population at large are expressed
as a broad concept of risk and a narrow one of
utility, e.g. for fellow human beings in need in
the third world, for the sick, or for nature. 
7.3 Advantages and drawbacks of 
different regulatory models
a. Formal regulation
One advantage of formal legislation is that it
can fulfil the functions described above, namely
to set standards, protect and regulate.
This ensures that the application of biotechno-
logy is not undertaken without control and
governance. One could say that the law is used
to delineate which of biotechnology’s potential
applications are desirable and which are to be
rejected. This can come from an assessment of
one or more of the ethical considerations that
have arisen. It may be judged that there is
insufficient financial or qualitative gain - e.g. on
the grounds of risk assessments - for a given
technology to be applied in a particular way, or
it is considered to be contrary to considerations
of dignity to admit a particular application.
Formal legislation can be essential when con-
sent does not provide adequate protection, e.g.
because the implicated parties’ circumstances
are not equal, or because a vulnerable individu-
al is involved. Moreover, formal legislation can
be necessary where fundamental values are at
stake, e.g. regard for future generations, for
the environment and so on - where the indivi-
dual may not perhaps feel responsible in the
same way and where the need for a general
ruling is therefore imperative.
Legislation can play an especially significant
role by emphasising the protective function.
Finally, formal legislation ensures that the pro-
cess is open and democratic.
A drawback of formal legislation is that it is dif-
ficult to be sufficiently precise as concerns ethi-
cal principles. If it becomes too vague, regula-
tion will fail to provide meaningful protection. If
it becomes too heavy-handed, it can risk
obstructing progress that is desirable, e.g. by
restricting research in an unintended fashion.
Moreover, it can appear as hostile among
affected parties, such as researchers and busi-
ness people, which can be detrimental. Finally,
legislation can strip from affected parties their
individual or professional responsibility and also
in this way be detrimental. And the law does
not necessarily render the affected parties ethical.
b. Framework legislation
The advantage of framework legislation is that
it indicates the specific forums - and hence
actors - who have a particular duty to partici-
pate in the ethical debate and decision-making
process. At the same time, pronounced flexibili-
ty is achieved, since it is up to these different
bodies to determine how a given task is to be
performed in detail and when, for example, an 
approval, a licence or similar is to be granted,
and when refused.
The drawback can be that it may be difficult for
the bodies in question to know which criteria to
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give detailed emphasis to when making an
assessment for a licence, an approval or simi-
lar. It is therefore important for such criteria to
be debated and drawn up - although not neces-
sarily in great detail.
c. Rules regarding consent
The advantage of rules regarding consent is
that decisive emphasis is given to autonomy.
This is appropriate where there is parity between
the consent giver and the consent receiver.
Moreover there is an assumption that there is a
coincidence of interest between the person
consenting and anyone consenting on their
behalf. Finally, it is important that the affected
parties are those embraced by the consent.
However, consent is an inappropriate or inade-
quate form of regulation in situations where no
parity exists between whoever is to give con-
sent and whoever is asking for it. This will at
times be the case, e.g. in relation to emplo-
yee/employer, insured/insurer, etc. Moreover,
consent can be problematical where a schism
arises between, for example, allowing the mot-
her alone or both the future parents to give
consent to research on embryos. Finally, as a
form of regulation consent assumes that there
is no regard for persons or interests beyond
the parties to the consent, e.g. future genera-
tions, sustainability, the vulnerability of the
natural world and so on.
d. Prohibition and sanction
The advantage of prohibition is that no issues
are allowed to evade social control, out of the
general principle that what is not prohibited is
normally permitted. This presupposes precision
in the drawing up of regulations.
The drawback of prohibition can be that it
appears to yield a prohibitive legal position
when compared to the needs and benefits that
arise in practice. It can be difficult to ensure
the flexibility which the dynamic development
of the biotechnology area can be said to create
a need for. One example is the prohibition on
cloning techniques, which may prove to impose
tight restrictions on any subsequent intentions
concerning stem-cell research, to the extent
that these require the use of cloning techniques. 
e. Professional standards
Professional standards have the advantage
that they are agreed upon, and that they the-
refore may be assumed to arise from internal
dialogue and consensus, which means that the
affected parties feel duty-bound to abide by the
agreed standards, even if they are not binding
- and, perhaps, abide not only by their letter,
but also by their spirit. At the same time, they
can be easier to amend than formal regulation
and so be more suited to the dynamic biotech-
nology area in a number of cases. They can in
this way have a significant conduct-regulating
function.
The drawback is that they do not include a bro-
ader ethical perspective, e.g. not necessarily all
questions relating to just distribution of bene-
fits and burdens, vulnerability and dignity, etc.
The specialist point of view may often be
expected to narrow the aspect of the values
and interests involved, since there is not, wit-
hin professional standards, the same tradition
for taking account of wider concerns of protec-
tion. The specialist professional standards are
centred chiefly on the traditional scientific need
for quality - and frequently on the need for
consent, regard for integrity, etc.
One particular development from soft to hard
law can occur, in that a regulation which starts
out as ”soft law” can become a ”locomotive” for
a development towards a more detailed legal
regulation of an area, and thereby also for
establishing binding legal rights for an area not
previously characterised by legislative codifica-
tion. This was the case, for example, with the
Declaration of Helsinki, which set forth the first
guidelines for the conduct of biomedical trials
on humans. This started out as a voluntary
professional code, but subsequently created the
background and learning environment for much
of the development which biomedical research
and the treatment of patients has undergone
over the past 30-40 years. In Denmark, for
example, the scientific ethical committees’ work
was established by law a decade ago, and this
will also happen in other countries as a conse-
quence of the directive on good clinical practice.
f. Case law
A clarification of the legal position by judges
has the advantage that a position is only taken
when a matter has evolved into a problem, and
that a position is taken only on precisely that
problem.
The drawbacks, however, are obvious. Case
law, where the legal development is laid down
by judges in the form of a ”patchwork” made
up of isolated cases, does not generally appear
to be especially suited to biotechnology. Firstly,
there will be uncertainty as regards what is
acceptable or unacceptable until the judgement
is made, and that can take a long time.
031 Lilla rapport  03/09/02  14:19  Side 50
51
Ethical principles in european regulation of biotechnology | Linda Nielsen | Berit A. Faber | April 2002
Secondly, it will be about a specific case, in
which only a small facet of biotechnology beco-
mes the object of legal clarification. Thirdly, it
will often be a question of a post factum ruling,
since the applications will be able to continue
while the cases are pending. Finally, economic
circumstances and, for example, questions
about who has the right to prosecute, will lead
to positions not being taken on the urgent
questions that biotechnology raises.
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8 The toolbox 
- check-list
The tools consist of two essentially different
instruments, which are here termed regulatory
models and debate models, respectively. The
following sketches out an abbreviated check-
list, which can form the background for deci-
sions on the application of the different tools as





• International conventions, directives
• National legislation of a substantive nature,
including prohibition, orders, rights, etc.
• Framework legislation to ensure authorisa-
tion procedures, etc.
• Case law
• Professional standards, etc.
• Provisions or practice concerning educa-
tion, information, debate and dialogue
8.1.1 Choice of forum
a. Is non-regulation (laissez-faire) appropriate
for the area, since supply and demand will
provide good support and control via the 
usual market mechanisms, or
- will the disadvantaged or vulnerable be 
left in the lurch?
- will control by the market be too simplistic?
- will non-regulation disregard groups which
cannot speak for themselves, including 
future generations?
b. Are professional standards appropriate, 
since there is agreement in the relevant 
group and the opportunity for sufficient 
development of broad and dynamic ethical
standards, or
- will it become more a question of a nar-
row, specialist point of view?
- will regulation become too expert-oriented
and without appreciation of the population’s
attitudes and the political level?
- will the ethical point of view become too 
narrow?
c. Is national regulation appropriate, since it 
ensures democratic control and (reinforced)
normative provisions and protection, or
- will the resulting state of law become too 
inflexible?
- will it be too difficult to amend?
- will it impede progress?
Or is formal regulation necessary to
- protect future generations and culture?
- ensure justice and balance interests?
- ensure that the Community’s (societal) 
interests prevail over individual demands?
- guarantee individuals’ rights (autonomy, 
non-discrimination etc.)?
d. Is international regulation appropriate, 
since ethical problems are international 
and protection is therefore better and equ-
ality is increased, or
- will it result in governance by the lowest 
common denominator?
- will decisions be too vague and imprecise?
- will protection be too weak?
In choosing a forum, account must obviously
be taken of what is possible, including conside-
ration of the difficulties of, for example, amen-
ding conventions, regulations, directives, etc.
At the same time, the choice of forum must
take account of whether the individual country
has a tradition of formal regulation or common
law. Finally, it will be crucial for the regulation
to offer suitable guidelines on the content of
the ethical assessment. Here, the type of regu-
lation chosen will be decisive.
8.1.2 Choice of type
a. Precautionary measures, which prescribe 
specific conduct?
- might be, for example, a prohibition, an 
order or a licence.
b. Prohibition model
- prohibits some specific research, objective,
conduct or similar.
c. Authorisation model
- possibly with built-in monitoring and 
inspection.
d. Rights model
- can create clarity
- can be difficult to manage and sanction.
e. Discretionary model
- can accommodate adjustment in line with 
new knowledge, methods, etc.
- many different concerns can be incorpora-
ted and balanced
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- important to define and limit what is to be
included in a discretionary consideration
- openness to interpretation may result in 
weak protection
- can be difficult to sanction
f. Revision model
- frequent assessments as to whether 
adjustments are required
- can involve uncertainty
- in practice, can be difficult to carry out 
even essential revisions.
g. Moratorium
- provides scope for an ethical pause for 
thought, without developments continuing 
unhindered
- can halt desirable development in a field
h. Education
- can ensure that ethical assessments are 
inculcated in researchers
- can ensure that ethical assessments become








• Future studies panels
• Values workshops
Use of this toolbox is an extension of the EU
Commission’s recommendation that societal
dialogue and monitoring are important factors,
which should accompany and direct the deve-
lopment of biotechnology. The platforms and
the ethical debate are comparable with the
classical agora, in which researchers, legisla-
tors, administrators, tradespeople and lay
people were convened. As emphasised by the
EU in its policy paper, public debate on biotech-
nology among researchers, industry and civil
society should be stimulated, and it is impor-
tant here that developers and marketers of
products assume a distinct ethical responsibility
for clarifying potential drawbacks and risks
which may occur in relation to the development
and utilisation of these products.
Ethical Councils
- ensure that competent individuals feel 
duty-bound to engage in the debate
- can act as advisors to decision-makers
- the question of membership must be care-
fully considered, including interdisciplinari-
ty, lay representation, parliamentary 
representation, etc.
- the question of modus operandi, including 
working groups, expert involvement, etc. 
must be considered
- How far one should go to achieve consensus
must be carefully weighed against the 
desire to emphasise the nature and value 
of the arguments.
8.2.1 Consensus conferences etc.
- consensus conferences, future studies 
workshops and similar can ensure breadth
in the public debate
- can be inventive with regard to how the 
debate is implemented and ”staged”
- can provide a pointer as to ”public 
opinion”
- the media can contribute to extending the 
debate
- narrative writing competitions, essay com-
petitions in schools, videos, etc. can be 
used to promote participation by the up 
and coming generation.
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• Conclusions and recommendations









Biotechnology has much to offer, and much
hope is pinned on its potential. However, at the
same time, the current and future applications
of biotechnology are cause for concern to the
extent that large groups of the general public
reject certain aspects of it - even where no evi-
dence has been found of any direct, substanti-
ve risk.
Ethics verbalises the values and the concerns -
although it necessarily draws on ”yesterday’s
words” to convey ”tomorrow’s concerns”. In
this report the main emphasis is given to the
following four ”sets” of ethical principles:
- Economic and qualitative benefits
- Autonomy, dignity, integrity and 
vulnerability
- Just distribution of benefits and burdens
- Co-determination and openness
Firstly, we address the question of how experi-
ence accumulated in the area of human health
(the ”human area”) may be applied to the
foods area as regards the incorporation of ethi-
cal principles in food control. A large body of
experience has gradually been amassed in this
area, and it would seem pertinent to seek to
apply these findings to the foods area; the
challenge being to determine whether ethical
principles should be incorporated more explicit-
ly in regulation.
Secondly, we consider the question of what
barriers and opportunities exist for further
operationalisation of these ethical principles in
regulating both the human health area and the
foods area. To that end, we propose a number
of tools that may be employed, while we also
present an analysis of what role the individual
actors in these areas might play as regards fur-
ther incorporation of ethical principles in deci-
sion-making processes and regulation.
”The Ethical Process” as a concept, and the
associated tools available may be illustrated by
the following model:
9.2 Can experience from the 
human area be applied to the 
foods area?
The following section highlights protection issu-
es, the risk assessments and the ethical princi-
ples that have prevailed respectively in the
health sector and the foods area, and examines
the extent to which principles and findings from
the health sector might be applied in the foods
area. This is a key issue in the light of the
trend in food and product regulation whereby
scientific risk assessment is made the arbiter of
whether marketing authorisations etc. are
granted, while in the health area the tradition
has to a far greater degree evolved so as to
incorporate ethical evaluation. 
a. Protection issues and ethical
principles in the health sector
Over the last fifteen years the public health
system in a number of countries has gradually
distilled off a number of issues concerning the
protection of patients receiving treatment from
the public health system, and serving as rese-
arch subjects in biomedical trials. These princi-
ples have been expressed formally in docu-
ments such as the Council of Europe’s
Convention on Human Rights and Biomedicine;
in the EU’s GCP Directive and in a large num-
ber of laws in the Member States. 
The ethical principle associated with economic
and qualitative benefits appears to have been
perceived as largely self-evident as it applies to
the health sector in the sense that health,
medical treatment and, by extension, medical
research, are regarded as qualitative benefits.
Examples of direct incorporation of the principle
are found in the requirement that there must
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be ”justification” for biomedical trials involving
human subjects, and in the Convention on
Human Rights and Biomedicine’s affirmation
that progress should be for the benefit of pre-
sent and future generations, and the principle
expressed in both this convention and in the
Unesco Declaration and according to which the
interests of the human being are to ”prevail
over the sole interest of society or science”.
The qualitative benefits in the sense of ”protec-
tion from risk” are assured through rules con-
cerning prior approval of biomedical research
projects, concerning ”good clinical practice”,
and concerning the responsibility of doctors for
medical treatment.
The protection issues that characterise protec-
tion of patients especially are autonomy, digni-
ty, integrity and vulnerability. This is illustrated
by the principle that medical treatment must
not be given without the patient’s informed
consent. This also means that medical doctors
and other health professionals have a duty to
inform patients of any undesirable effects asso-
ciated with a treatment, and to inform them of
alternatives to the therapy proposed. The ind-
ividual is also entitled to choose to be informed
of his/her health condition or to refrain from
receiving such information (the ”right not to
know”). Moreover, health legislation comprises
a number of provisions for protection of especi-
ally vulnerable groups such as the elderly, chil-
dren and individuals incapable of giving infor-
med consent to medical treatment. Protection
of integrity is ensured through rules governing
confidentiality in the doctor-patient relations-
hip, including the doctor’s duty of non disclosu-
re, together with the sanctity of private life,
including the right to protection against perso-
nal health data being made public, and rules
concerning non disclosure of personal data
relating to medical information. Human dignity
is also emphasised in the Convention on
Human Rights and Biomedicine.
Just distribution of benefits and burdens is a
principle implemented primarily at the interna-
tional level. The Convention on Human Rights
and Biomedicine, for example, emphasises
equal access to health services, while the
Unesco Declaration asserts that the benefits of
the technologies employed must be made avai-
lable to all. 
Co-determination and openness are emphasi-
sed as highly important principles by the EU,
the Council of Europe and via a large number
of national measures (see Chapter 7 for further
discussion). 
The principal characteristic of the rules applying
in the health area, and that protect patients
and research subjects is primarily the protec-
tion of all persons, i.e. a highly individual-ori-
ented protection issue. Other ethical principles
than respect for the rights of the individual are
found in regulations on artificial insemination,
which in certain countries entail considerations
beyond traditional health issues. Restrictions
applying to the individual informed by social
and religious values are expressed as restric-
tions on who is entitled to receive artificial
insemination so that, for example, doctors are
not permitted to artificially inseminate lesbian
women, or as prohibitions against the donation
of eggs and/or embryos. 
b. The foods area - substantial
equivalence - the precautionary
principle - sustainability
In the foods area, the basic premise is to
employ the scientific principles that have been
elaborated and refined over the years. The fol-
lowing section describes the progression in this
area from the principle of substantial equiva-
lence towards, on the one hand, the precautio-
nary principle, which has informed international
regulatory efforts over the last few decades,
and on the other hand, the principle of sustai-
nability, and for each of these principles discus-
ses the possibility of transcending purely scien-
tific considerations to incorporate ethical princi-
ples.
The principle of substantial equivalence5 was
first described by WHO and the OECD in special
reference to foods derived by modern biotech-
nology. According to the OECD definition, exis-
ting whole foods may be used as a basis for
comparison when assessing the safety of novel
or modified foods. If the novel food is found to
be comparable with its traditional counterpart
in toxicological and nutrient testing, it may be
treated in the same way as that counterpart in
respect of its safety. Official safety assessments
take account of whether proteins are formed
that might give rise to allergic reactions, and of
deviations in constituent protein, fat, vitamins,
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etc. With regard to deviations as compared
with traditional counterparts, novel foods must
be assessed on the basis of their unique consti-
tuents and properties. Equating foods in this
way lends consistency to safety assessments of
GMO-based foods versus non-GMO-based
foods, but constitutes neither a safety assess-
ment nor a foods assessment per se. As such,
the principle lends itself purely to scientific risk
assessment, and admits no ethical concerns.
The precautionary principle has found favour as
a new principle in international legislation. This
has happened after GMO-based products in
many parts of the world have been met with
growing resistance, and doubts as to whether
or not they might result in serious, widespread
and irreversible damage have been mounting.
The precautionary principle is gaining ground in
spite of the fact that EU legislation operates
with no explicit definition of what the principle
actually embodies. In a communication from
2000, the European Commission 20006 offers
its recommendations for how the principle
should be interpreted within the EU: ”In order
to protect the environment, the precautionary
approach shall be widely applied by States
according to their capacity. Where there are
threats of serious or irreversible damage lack
of full scientific certainty shall not be used as a
reason for postponing cost-effective measures
to prevent environmental degradation.”
The salient issue here is that the precautionary
principle can be applied in cases where the sci-
entific evidence is insufficient or uncertain, and
preliminary scientific assessment indicates that
there is reason to assume that the degree of
risk to the environment and human, animal and
plant health would be in conflict with the high
standard of protection prescribed by the EU.
Application of the precautionary principle also
requires that the burden of proof be shifted.
Hence it is no longer the authorities or the
public sector that has to provide proof of harm-
ful impacts, but rather the applicant seeking to
place GMO-based foods on the market, for
example. The principle also requires that a
given application be reasonably certain and
that no preferable alternatives exist. Finally,
the principle emphasises the necessity of open,
democratic decision-making processes.
The precautionary principle thus permits rejec-
tion when insufficient scientific certainty exists
to vouchsafe the safety of the product.
However, it is far from given that the precautio-
nary principle would cover a situation in which
there were no question of scientific uncertainty,
but rather a move to reject a product on other
(ethical) grounds. If we consider a parallel situ-
ation in human health - human cloning - it is
then possible to take into account the view that
has dominated the debate (certainly in the
Western World), this being ”this is unacceptable
under any circumstances”. This attitude is infor-
med by an altogether different premise from
that of scientific risk assessment. But it does
not sort as readily under the precautionary
principle when referring to GMO-based pro-
ducts. 
The principle of sustainability rests on the pre-
cept that sustainability must be assured with
respect to use of natural resources, to environ-
mental issues and so forth. The definition per-
mits ethical evaluation, but has not by tradition
been applied with a focus on the ethical slant
of the principle of sustainability. The move
away from the principle of substantial equiva-
lence, the precept of which is presumptive (”If
it looks familiar, then that’s good enough”)
through the precautionary principle (”If it does-
n’t look familiar, and might involve a risk to
human health and the environment, then we
need proof that it’s not damaging before we
can say it is good enough”), to the principle of
sustainability (”If sustainability is at risk, then
it has to be rejected”) represents a progression
from narrow to broad risk assessment. This
shift consequently affords us more scope in
determining where the risks lie, how they are
to be measured and who has to prove what.
But these principles would all appear to be
evolving out of a scientific premise. The ques-
tion remains ”Is it safe for humankind and
nature?”, but there is no room for the question
”Is it right for humankind and nature?”. 
The precautionary principle and the principle of
sustainability allow only limited scope for ethi-
cal considerations that are not based on scien-
tific rationale, i.e. in relation to medicinal pro-
ducts, and to a limited extent to the Directive
on Deliberate Release, but not in relation to
concrete ethical provisions concerning authori-
sations for placing such products on the mar-
ket. The reason that the named principles have
taken on this format and sphere of application
presumably derives from the fact that they
concern products that are differently and more
immediately bound up with free mobility, the
wish for non-discrimination, etc. - these being
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key issues for both the EU and the WTO.
Consequently, for GMO-based foods, the ten-
dency has been to allow decisions concerning
marketing authorisations in the EU to be based
solely on scientific risk assessments. 
This begs the question of whether scientific
principles should not be complemented by a ”
principle of ethical precaution” in evaluations of
the extent to which research should be under-
taken on a particular product, or whether mar-
keting authorisation should be granted. 
9.3 Ethical principles 
in the foods area?
As highlighted in the section on risk assess-
ment, biotechnology raises issues concerning
both risks and values, and scientific risk
assessments alone cannot embrace the scope
of the value-based issues underlying the entire
GMO debate. There is no sharp divide between
scientific risk assessments and political risk
management; risk management is not a well-
structured balancing of costs and benefits, and
risk communication does not address the
dilemma between the actual (objective) risk
and the perceived (subjective) risk in which
knowledge and values are commingled. 
It is our position that the key aim in this con-
text is to link up all the elements of scientific
risk assessment and political risk management
and the dialogue on risk management to ethical
considerations and evaluations.
Two examples will serve to illustrate the pro-
blem, and the difference between scientific risk
assessments and values-based, ethical assess-
ments:
In recent years the debate on BSE has indica-
ted clearly that it is not merely a matter of sci-
entific risk assessment that determines whet-
her or not the public can accept exposure to a
risk. And yet the risk of contracting BSE by
eating beef proved slight, and for the experts
the force of public reaction was something of a
mystery. The reason for the force of the reac-
tion against this particular risk may possibly be
traced back to the fact that people felt that
behind it all, certain ethical principles had been
violated, when it emerged that the disease was
thought to have arisen when cattle were fed on
feed enriched with bone-meal, that is, feed
containing residues from animal cadavers.
Many presumably felt that it was ”unnatural
and against nature” to feed cattle with animal-
based feed, given that cattle are herbivores. In
this context it is important to recognise that in
the public’s perception of their willingness to
accept exposure to risk a number of ethical
issues and concerns are also involved, which
may not necessarily be expressed as such, but
that nevertheless strongly influence public
opinion. This meant that while the arguments
were based on scientific risk assessment, the
reactions were conceivably based on ethical
evaluations. 
To take a hypothetical scenario: if we were to
arrive in a situation where an initiative was
proposed in the foods area along the lines of
the example of human cloning, the problem
might occur in a pure form. If, for example, it
proved cost-efficient and safe (by scientific
standards) to produce meat by culturing human
muscle tissue outside the body using genetic
engineering, then the scientific principles would
not necessarily ensure that such a product
would be the object of ethical deliberations.
Indeed, access to a cheap and perhaps very
healthy and nutritious source of protein might
conceivably be justified by socio-economic
interests in access to affordable protein for
poverty-stricken populations. Nonetheless we
can readily conjecture that there would be a
lack of acceptance of a food of this nature
based on ethical evaluations - in line with
public rejection of cloning (and possibly dra-
wing on parallels with cannibalism). 
The need to be able to make ethical evalua-
tions with respect to food products also would
thus appear to be present. An important objec-
tive for democratic and dialogue-oriented risk
management and risk communication must be
to open up the parameters for legitimate objec-
tions that would also comprise wider ethical
issues. Against this background it is useful to
examine the four ethical principles addressed in
this report, and to explore whether there is
justification in the foods area as regards pro-
duct marketing to address the same protection
issues as those involved in human health con-
cerns. 
The ethical principle associated with economic
and qualitative benefits has a more restricted
role with respect to the marketing of products
in the foods sector than it has in the health
sector. Genetically modified foods are scarcely
perceived as a qualitative benefit comparable
with the offerings of the health sector, including
medicinal products. One interesting idea would
be an ethical assessment of whether there was
”justification” for research, deliberate release or
product marketing on the basis of an assess-
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ment of economic and qualitative benefit. In
that context it would presumably be most
realistic to apply any ethical considerations at
an early stage rather than at the product mar-
keting stage. One aspect that also arises in this
context is the environmental issue and thereby
also concern for future generations. Here it is
important to consider which decisions would be
irreversible. 
Autonomy, dignity, integrity, and vulnerability
do not amount to the same central issue in the
foods area as they do in the health area. The
vulnerability of nature is an element in protec-
tion of the environment and biodiversity, while
dignity, integrity and vulnerability are principal-
ly associated with the human area in that they
concern protection of the human being. The
principle of autonomy, however, can be readily
applied to the foods and product area. The
principle of free information and the individual’s
freedom of choice might suggest a principle of
autonomy with regard to whether or not the
individual wishes to consume genetically mod-
ified foods. This would then entail a need for
measures to ensure that labelling at every
stage in the food processing chain clearly ind-
icated genetically modified content. However, it
is arguable whether labelling of this nature
designed to observe the need for autonomy
should be required in instances of significant
GMO content, or in all instances. 
Just distribution of benefits and burdens is a
principle found primarily at the international
level. The Unesco Declaration, for example,
stresses that the benefits of work on the
human genome must be made available to all.
In this context it is important to be aware that
while ethical evaluation might result in restric-
tions on GM foods, they might conversely result
in measures to promote them in so far as they
improve the capacity to feed people in the
developing countries, for example. The princip-
le is also expressed in the principle of sustaina-
bility and the Convention on Human Rights and
Biomedicine. 
Openness and co-determination are emphasi-
sed as key principles by the EU, the Council of
Europe, the Aarhus convention on the environ-
ment and a large number of national initiatives
(see Chapter 5 for a more detailed discussion).
In that context it is important to be aware of at
least three factors. Firstly, that the ethical pro-
cess seeks consensus, but if this is regarded as
unattainable the process will aim for ”fair play
despite differences”. Secondly, it is important to
respect arguments based on wisdom on an
equal footing with those informed by a scienti-
fic rationale, and to acknowledge that ethical
arguments can be just as valid as economic
arguments. Thirdly, it is important to prescribe
regulation and practice in such a way that they
respect the individual consumer’s autonomy
and freedom of choice so as to prevent ethical
”vote-down” of minority views on issues where
no positions aimed at the common good and no
concern for future generations necessitate a
common position in violation of the individual’s
freedom of choice. To that end, regard for
Europe’s new multicultural societies might sup-
port a move to create regulatory scope for dif-
ferentiated freedoms of choice that do not con-
flict with concern for the common good. It is
important to link ethical principles up with dia-
logue between those directly affected and the
state, in order to arrive at a viable decision-
making process on the use of novel biotechno-
logy in the foods area.
9.4 How are ethical principles 
operationalised in regulations?
Any detailed discussion of how ethical principles
may be incorporated and operationalised in
decision-making processes and regulation pre-
supposes that the component barriers, assump-
tions and possibilities have been crystallised
out, and that a number of central questions
have been settled concerning political will,
scope, actors, timing and choice of tools. But
by way of introduction we can now summarise
which ethical principles and regulatory chal-
lenges are involved:
9.4.1 Regulatory challenges and 
possible tools
The object is to ensure that certainly the four
fundamental ethical principles discussed in the
foregoing of benefits, autonomy, just distribu-
tion and co-determination are incorporated in
regulation of biotechnology. 
International regulation is characterised by two
different trends: 
Firstly, there are a number of international
conventions, declarations, etc. that emphasise
very broad, general ethical principles. This
applies to the human area, e.g. the Unesco
Universal Declaration on the Human Genome
and Human Rights, the Council of Europe’s
Convention on Human Rights and Biomedicine
and the EU Charter of Fundamental Rights from
2000. Rights in this context are centred especi-
ally on the ethical principle associated with
autonomy, dignity and integrity, and to some
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extent the just distribution of benefits and bur-
dens. In the environmental and foods area
ethical principles do not apply in a narrow
sense, but rather to general principles of ”the
right to the environment”, the precautionary
principle and the principle of sustainability.
However, to some extent the ethical principle
discussed in the foregoing, of openness and co-
determination, comes into force in, for examp-
le, judicial rules concerning hearings. 
Secondly, there are the precise provisions,
directives, etc. in the EU domain governing a
number of issues. This applies to the EU direc-
tive on clinical trials on medicinal products for
human use. However, it applies especially to EU
provisions and directives concerning foods,
which by means of comprehensive and complex
authorisation schemes enforce risk assessment
for health and the environment, and the label-
ling of GM foods. 
National regulation is particularly relevant in
the human area, especially in connection with
medical treatment, since the foods area is lar-
gely covered by EU controls - usually in the
form of total harmonisation. In the human area
regulation varies considerably when it comes to
intensity, content and format, thought there
still a number of areas that have resulted in
national regulation, e.g. artificial fertilisation,
genetic testing and gene therapy, cloning and
(future) biobanks. In this way the ethical prin-
ciples concerning autonomy, dignity, integrity,
etc. are often covered. In addition there is the
regulation that creates the framework for ethics
committees and the like, the purpose of which
is to secure information and debate on ethical
issues relating to biotechnology in one form or
another and/or which have a specific mandate
to grant authorisations for certain applications
of biotechnology. 
In the health area there is thus extensive scope
for incorporating ethical principles in decision-
making processes and regulation. In the foods
area the scope of individual nations for incorpo-
rating ethical principles is, however, limited
when it comes to product marketing as a result
of the goal of total harmonisation based on
rules that do not give scope for ethical conside-
rations. The foods area is extensively covered
by WTO rules, which give precedence to the
principle of free trade, and thereby focus more
on eliminating barriers to trade than promoting
ethical concerns. Nonetheless, WTO agree-
ments and rulings reveal that other concerns 
do find favour - for example, the concern
regarding exhaustible natural resources and
public order enabling consideration of ”public
order and morality”. It is hence worth conside-
ring to what extent these new trends may be
employed in introducing ethical considerations
when these have sufficient primacy and impor-
tance.
This report presents a whole series of tools that
can be used in operationalising ethical princi-
ples. These are divided up into the so-called
”debate models” and ”regulation models”, and
the report highlights a number of the benefits
and drawbacks of the individual models.







• Future studies panels
• Values workshops
The regulation models consist of 
Toolbox
Regulatory models
• International conventions, directives
• National legislation of a substantive nature,
including prohibition, orders, rights, etc.
• Framework legislation to ensure authorisa-
tion procedures, etc.
• Case law
• Professional standards, etc.
• Provisions or practice concerning educa-
tion, information, debate and dialogue
A checklist is provided for the purpose of high-
lighting a number of factors that in any event
should be addressed in considering the applica-
bility of the various models. 
9.4.2 Political will 
and regulatory scope
If there is to be greater operationalisation of
ethical principles in regulation than happens
currently, it is essential that the political will is
present to realise this aim. This applies at
national level to parliaments, governments,
authorities, etc. It also applies at international
level to international forums of various kinds.
Under EU auspices it is especially important
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that a political commitment is expressed by the
European Parliament and the Council of
Ministers to greater operationalisation of ethical
principles in regulations, and that this is sup-
ported and implemented by the European
Commission. In that context it is significant
that the EU Commission in its communication
Life Sciences and Biotechnology - A strategy for
Europe, which was ratified by the EU Council of
Ministers, chose to emphasise that the life sci-
ences and biotechnology should be developed
in conformance with ethical values and social
objectives.
The Commission also emphasises the impor-
tance of promoting information and dialogue
with a view to giving the public and affected
parties a better means of understanding and
assessing the complex issues associated with
the application of biotechnology and of develo-
ping criteria, including ethical guidelines/norms
and methods for weighing up the benefits
against the drawbacks and risks. Exactly how
operationalisation on these lines might be
brought about will depend on what options and
restrictions present regulation comprises.
The restrictions against incorporating ethical
principles in regulation currently derive from
statutory instruments, directives, etc. according
to which total harmonisation is achieved for an
entire area. This applies to a proportion of EU
regulation in the foods area, for example,
which means that it is not possible to incorpo-
rate and operationalise ethical principles wit-
hout amendment of these rules or the introduc-
tion by some other means of, e.g. the ethical
principle of co-determination and openness. 
It is therefore important that this type of regu-
lation is elaborated in such a way that it gives
scope for ethical considerations. Examples of
an opening up for the possibility of incorpora-
ting ethical considerations exist in the patents
directive and the directive on deliberate relea-
se. These directives open up for the possibility
of consulting the EGE (European Group on
Ethics in Science and New Technologies) on
principal ethical concerns raised by the directi-
ves. However, the difficulty lies in establishing
exactly what the ethical principles cover, how
they should be interpreted and how they
should be incorporated in the processing of
actual applications.
9.4.3 Actors: role 
and scope of action
In connection with operationalisation of the
ethical principles it is essential to carry out an
analysis of actors in order to ensure that the
right ones are involved, and to consider how
the actors themselves can further promote the
application of ethical principles.
Actors
Who are the actors?
• Researchers
• Commercial actors
• Affected parties (environmental groups, 
patient associations, other interest groups)
• Decision-makers (politicians)
• Administrators (public authorities)
• The media and communication
• The general public/lay people
a. Researchers are usually first on the scene.
Researchers have an important role to play as
regards observation of ethical principles in the
sense that they are both the suppliers of speci-
alist knowledge of the research and its possible
applications, and the suppliers of research on
ethics and on the social impacts of biotechnolo-
gy. While academics in pure science and the
health sciences will often be qualified to com-
ment on aspirations regarding the application
of research in industry and in combating disea-
se, other academics, such as sociologists, psy-
chologists will be needed to comment on the
consequences for society at large, human inter-
action, self-perception and so forth. An inter-
disciplinary approach to the problems is there-
fore crucial. In this context it is also important
for academic institutions to assume a responsi-
bility for generating and supporting the inter-
disciplinary approach required in addressing
biotechnology issues, especially as the initiators
of forums for encouraging knowledge exchange
among the different disciplines.
Generating knowledge
• Who possesses what type of knowledge?
• Researchers - typically work with baseline 
data and generate information from this
• They generate expert knowledge, typically
of a technical/scientific nature
• Generated knowledge: expert knowledge -
information
• Law, sociology, ethics, philosophy are 
meta-disciplines that incorporate raw data 
produced by (pure) science
In operationalising ethical principles the roles of
researchers can be developed in various ways.
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One approach is for ethics to be incorporated
more extensively in the training received by
pure scientists so that they may be better
qualified to engage in ethical debate, and per-
haps also have a greater sense of duty to initi-
ate debate in their particular field of research
(see Chapter 8). Furthermore there is a need
for greater involvement of researchers in the
social sciences and humanities. Finally, it is
vital to establish forums, in which researchers
can engage in dialogue with counterpart acade-
mics and thereby contribute to the factual
information generated, while also helping to
identify present and future ethical dilemmas in
a given issue.
b. Commercial actors and affected parties
will often have a direct and transparent interest
in a specific application of biotechnology, e.g.
as a patient hoping for a new medical cure or
as the manufacturers of GMO-based foods.
Moreover, affected parties may include persons
and groups with a highly differentiated appro-
ach to the problems, e.g. as environmental
watchdogs, lobbyists for the precautionary prin-
ciple, etc. 
When it comes to operationalising the ethical
principles, the role of commercial actors can be
extended by promoting their involvement in
forums comparable to those for researchers.
This would be valuable for several reasons.
Firstly because ”the ethical dilemma” might be
”bad for business” in the sense that sales may
fail if the product in question is regarded as
ethically undesirable. Secondly, because com-
mercial actors, like other citizens have a shared
responsibility (and often desire) to engage in,
and contribute to, ethical debate in their line of
business. Other affected parties such as patient
associations could be represented in issue-spe-
cific ethics committees. Interest groups can be
encourage to participate by means of ”the right
to know”, hearings, representation in ethics
committees, the right of complaint, court trials
and the like. The model produced by the
Norwegian values workshop on the future of
the fisheries industry (see Chapter 6) could be
held up as inspiration for initiating a sector-
wide debate in other countries. On these lines
it might be observed that the pharmaceuticals
industry is approaching a stage where ethical
considerations will be a competitive parameter.
c. Decision-makers are required to draw on
facts, evaluations and ethical choices to deter-
mine the extent to which, and the manner in
which, ethical principles are to be observed. For
these actors, tools are crucial. 
In places where no ethical councils exist, these
should ideally be established to undertake
informative, debate-promoting and advisory
programmes in order to give decision-makers a
qualified basis for addressing ethical issues.
The existence of such ethical councils could
also be assured by means of legislation.
Furthermore there is of course the key role to
be played by decision-makers, that is, initiating
the incorporation of ethical principles and con-
siderations in definitive rulings and regulatory
processes. This could be in the shape of nor-
mative work on ethical components, but often
it might also be a pertinent element in regula-
tion of processes, in order to ensure the exis-
tence of official bodies and procedures for con-
ducting the actual ethical evaluations. However,
to that end it is vital for decision-makers to go
one step further and also supervise the elabo-
ration of guidelines by which the ethical princi-
ples may be defined and operationalised. One
example is the EU directive on good clinical
practice and the Danish act on a scientific
ethics committee system (see Chapter 4 and
Chapter 6), both of which present a detailed
check-list for the evaluation to be conducted by
scientific ethics committees in vetting proposed
research projects. 
d. Administrators are mandated to implement
the letter and ”spirit” of the law in authorisa-
tion procedures, etc. This may be straightfor-
ward when the criteria are explicit, but the
ethical principles will often be relatively vague
in the sense that they are open to a wide array
of interpretations, ranging from the strictest
interpretation of what constitutes a violation of
the principles of integrity and vulnerability, for
example, to a more lax interpretation. The
more accommodating the legal norms are, the
greater the decision-making authority will be
among administrators. This makes the way in
which approval bodies, for example, are
appointed and made up all the more decisive. 
Knowledge governance
• Administrators - work with information, 
but rarely do more than simplify and com-
municate this knowledge - to affected par-
ties (applicants, etc.), politicians and the 
public
• They do not generate a new type of know-
ledge, but process expert knowledge.
• Generated knowledge: processed expert 
knowledge/information
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When coordinating process regulation and
developing guidelines for decisions on actual
applications, administrators, like decision-
makers, require ethical information and exter-
nal evaluations. They may also need more
explicit policy-based statements as to which
ethical principles are to be incorporated in an
administrative regulation; an evaluation of an
application and how these are to be weighted
in relation to each other.
Ideally, the EU should play an extended role in
promoting the interdisciplinary approach in
relation to the administrative level also in such
a way that ethical issues concerning the human
area, animals area, plant area and foods area
may be considered and appraised across the
board. 
e. The media and communication The media
have an important role to play in communica-
ting information and as initiators and central
co-actors in national debate. They often have a
constructive contribution to make to debate,
but are not bound by the same obligations con-
cerning balanced and consistent views that are
imposed on decision-makers, administrators,
etc.
Ideally, the media should also communicate
and promote debate on topics that transcend
sensationalism or ”war” between conflicting
interests to contribute to a more nuanced
debate.
When it comes to communication of risks, it is
important to ensure that this is not regarded as
a one-way push to convince the public that
genetic engineering per se is to the good and a
sign of technological progress. The latest
Eurobarometer polls of public opinions on bio-
technology have also revealed that it is not
public’s level of understanding of the technolo-
gies involved that determines their attitudes to
the technology. Instead, risk communication
should be a ”multi-channel” communication in
which several actors join forces and return
input to each other. Scientists, decision-makers
and administrators will in this way not only be
suppliers of output, but also recipients of out-
put from industry, interest groups, lay people,
etc. 
f. The general public/lay people are impor-
tant actors as regards the safeguarding and
communication of the ”wisdom” present among
them. The public needs to be consulted, and
society as a whole needs the public to contribu-
te with the wisdom it embodies. 
Wisdom?
• Wisdom is generated from data - informa-
tion, but who does this, and who posses-
ses wisdom?
• If scientists and decision-makers process 
information on the basis of ethical princi-
ples, perhaps wisdom can be generated?
• Is it also true to say that wisdom exists in 
the population, when considering ethical 
decision-making processes - and that 
Scandinavia’s tradition for using lay people
in various organisations, councils and 
boards may be interpreted as recognition 
of this wisdom?
It is important that lay opinions are made on a
well-informed basis. The foundation for lay
opinion might be achieved by: a thorough
grounding in the topics to be assessed, inclu-
ding access to expert opinion such as a dedica-
ted secretariat that can provide specialist
knowledge geared to lay people so that their
opinions may be well-informed and supported
by the facts. At the same time it must be ensu-
red that there is scope for lay people to form
their opinions without being voted down by for-
mally qualified experts. Here again, the
Norwegian model, in which lay people help to
define and weigh up a number of ethical princi-
ples in an ethical matrix can provide inspira-
tion. Lay people should be included both as
participants in public debate and as active
members of ethics committees both in consul-
tative forums and on committees set up to vet
specific projects.
The domain occupied by the actors addressing
the new biotechnology creates a need for a
type of forum in which the term agora from
ancient Greece can serve as inspiration. This is
a form of market place, established by deci-
sion-makers with the aim of convening actors
(stakeholders) to exchange views with each
other and the general public. In ancient Greece
this was where public administrators, the judi-
ciary, philosophers and traders assembled to
administrate, exchange views and do business.
At a time where science and its application is a
multinational issue that will also have impact
on future generations,  should be established at
local, national and international levels alike.
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9.4.4 Debate: polycentrism 
and timing
As stated, elements from many different dis-
courses and contributions are involved in ethi-
cal debate and in the decision-making process
concerning regulation.
The generation of a form of ethical consensus
is a process akin to theories concerning poly-
centrism in law. Law is created not only within
a single forum, but in many different centres.
The formation of laws is therefore not a mono-
centric process, but is polycentric in that it
goes on in several spheres and is the object of
dynamic exchange among different centres and
levels. The legal experts Henrik Zahle and
Hanne Petersen in Denmark have explored this
theory of polycentrism in legal science.
The ethical process is characterised by the
same polycentrism. Ethics are no longer formu-
lated by a single proponent (for example the
church) but are evolved in an interaction of for-
ums and actors. If a legislator or authority wis-
hes to promote ethical debate it is therefore
important to analyse out the actors in order to
initiate an ethical debate among their ranks
(for example, in the particular sector that will
be affected such as the food industry, agricultu-
re or pharmaceutical industry). It is then also
important to link up the debate ongoing at the
different centres - who will be talking to whom
so that we can be sure that an opinion is gen-
erated on the issue to be settled? Moreover it
is important to sustain debate and dialogue -
how do we ensure that debate and dialogue do
not peter out - how is momentum sustained?
A polycentric debate should be a phase devoted
to settling issues and discussing them and the-
reby the precursor of a process to arrive at an
enhanced regulation strategy based on a clear
perspective of the general public’s and the
actors’ attitudes to an issue prior to legislation.
The debate phase calls for both an interdiscipli-
nary component and recourse to the wisdom
embodied by the general public. In this context
the media have an important role to play, and
the various forms of debate model can be
employed depending on culture, traditions and
so forth.
Timing is an element that is essential to stress
in connection with ethical debate. The Danish
Council of Ethics has adopted the motto ”Ethics
Just In Time”. As the words suggest, this
means that ethical debate must not happen to
late, but nor must it start too early. If ethical
debate comes too late, products will already be
placed on the market, and the risk is that there
is no issue left to debate.
If it happens to early the risk is that no one will
have any feel for the issues. The questions will
not be taken seriously and ethical debate will
fall by the wayside. Two examples of this will
serve to illustrate the problem:
In the mid-1980s the then Danish Ministry of
Health produced a report for the Danish
Parliament, Folketinget, on gene therapy.
This was met by deafening silence - simply
because the issue had been raised too early.
The same was the case with the debate on
Dolly, the first cloned sheep. Everyone claimed
that the public was astonished that cloning was
even possible, despite the fact that a study of
newspaper cuttings revealed that the capability
had been reported in newspaper articles for
several years previously.
It thus important to plan the timing of ethical
debate and the operationalisation of ethical
principles. This should be based on an assess-
ment of when the debate will be sufficiently
newsworthy and merited. Perhaps it should be
conceded that what is really needed is ”Ethics
All the Time” - when research is planned, when
it is carried out, when its results are studied,
and when it is applied.
9.5 A choice of tools
In the following we discuss the tools available
in the various areas. It should be strongly
emphasised that these are not proposed as
definitive and absolute solutions, and are rather
suggestions for providing a point of departure
for forming opinions. In proposing these as
tentative solutions it is in recognition of the
fact that it is often more productive to address
a concrete issue than to have to begin delibera-
tions ”from scratch”. The proposed solutions
should, however, be adapted to the given situa-
tion, culture, tradition, etc.
The following also proposes how the ”buffet” of
options can be worked into set ”menus” com-
prising ”starters”, ”main courses” and desserts,
i.e. debate models, international regulation and
national regulations (and professional norms).
9.5.1 The debate models
The ”starters” are the debate models. In our
opinion these are all-essential both as a demo-
cratic component for ensuring openness and
co-determination, and for testing out the pro-
spects of achieving acceptance and even con-
sensus on a given issue. It is important to
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establish forums from which ethical debate can
be initiated. Debate should engage both those
directly affected and the general public, who
should be assured of the right to information
and participation in decision-making (cf. the
Aarhus Convention). Both interdisciplinarity and
the incorporation of lay wisdom are essential in
this context. It is equally important that ethical
debate is taken seriously rather than ending up
as a ”show dish”. If the general position is that
the application of certain aspects of biotechno-
logy is undesirable then this should be respec-
ted. In order to ensure broad debate, formal
regulation - national and international - should
establish forums in which ethical debate can
flourish. 
These then are ”menus” offering many varia-
tions on the ”starters”, but these must not be
omitted, since this would ”send the guests
home hungry”. 
9.5.2 National regulation
Besides ensuring ethical debate, proper formal
regulation at the national level is especially
important when it comes to areas not governed
by binding EU regulation, and where the follo-
wing circumstances obtain:
a. Where there is a need to protect future 
generations. 
In instances where sustainability is an 
issue, for example.
b. Areas where cultural considerations are 
involved.
Where the issue concerns treatment of 
embryos for example.
c. Protection of groups in the population 
unable to look after their own interests. 
(vulnerable groups)
Where the issue concerns children, people 
with mental disorders or senile dementia 
for example.
d. Situations in which there is inequity 
between those affected (dependency).
The issue might be genetic testing in the 
context of employee/employer or 
insured/insurer for example.
e. Cases where competence needs to be 
ascertained. 
Concerning the right to artificial insemina-
tion for example.
f. Areas in which automony must be protected.
In questions of rules regarding informed 
consent or information, for example.
Many of these areas will also be suited to inter-
national regulation, but in a number of areas
there will be a distinct difference in how ethical
opinion ”turns out”. A typical example is ”the
status of the embryo”. Generally there may be
a difference among nations (national trade-
marks) as a result of:
- religion
- state/individual
- national economy/social conditions
- regulatory tradition
- other
It should presumably be accepted that in such
cases that it will not possible to reach agree-
ment (as things stand) at the international
level, nor within the EU. By achieving the right
”timing” the process involving formal regulation
will also be able to help to establish the norma-
tive function that might promote (wider) accep-
tance of a specific application of biotechnology.
However, this should be achieved without any
ethical ”vote-down” of minority views. In order
to guard against ”ethical minimalism” it is
essential that such principles are contained in
substantive, content-specific regulation.
Moreover, it may be expedient to aim for more
”process oriented” regulation, for example, in
the form of scientifically-based ethical evalua-
tion of specific biotechnological (biomedical)
projects. When framework legislation is passed,
it is of great importance that relatively detailed
and explicit guidelines are provided for which
components are to be comprised by ethical
evaluation, and according to which principles
the concerns are to be weighed up. All too
often there is a ”quantum leap” between very
generally adopted ethical principles and actual
position, and guidance on how this leap is to be
made should be comprised by motives or admi-
nistrative guidelines for the evaluation for
example.
9.5.3 International regulation
Many components laid down in national regula-
tions will also have relevance for international
regulation. In the following we indicate areas
that would appear of particular importance and
pertinent to take account of in the international
domain.
It is essential to establish formal prohibitive
regulation or the like under international auspi-
ces in areas where there may be a significant
risk for the next generation, for example, in
relation to:
- the environment
- reproduction (e.g. reproductive cloning)
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- irreversible damage
- epidemic impacts (xenotransplantation?).
Besides these, other notable areas in which
international regulation might be appropriate
would include consumer protection, quality cri-
teria for, e.g. biobank storage and labelling
(traceability) of GM foods, for example. Another
area undergoing extensive internationalisation
is biomedical trials. The pharmaceuticals indus-
try’s internationalisation of clinical trials has
stepped up the need for universal rules for
ensuring sufficient scientifically based ethical
scrutiny of trials involving human subjects.
Internationalisation calls for international rules,
but also for international networks - in the field
of scientific ethics there will be a need for net-
working among the committees set up to
address the specific problems associated with
scientifically based ethical scrutiny.
A number of the areas discussed in more detail
below in the context of national regulation (for
example, the protection of employees and the
insured) might also benefit from an internatio-
nal format. The issues involve a degree of
”Europeanisation” of the ethical questions and
answers, which will presumably result in grea-
ter consensus over time in the areas discussed. 
9.6 Conclusion
The dilemma facing regulatory bodies is often
referred to in very negative terms as a choice
of either major principles and lofty, vague,
concrete rules borne out of consensus, but
which out of ignorance of the technologies are
condemned to insignificance, or, explicit, preci-
se rules that are restrictive and only prescribe
for current issues and are therefore condemned
to premature obsolescence.
In our opinion this pessimism is neither helpful
nor justified. However, it is true to say that the
outcome of research is essentially unpredicta-
ble, and that this presents an obstacle to the
aim for regulation to draw on predictable valu-
es. But by employing models that contain both
robust international ”brake pads” at the all-
essential level, and also flexible regulatory
models, such as debate models and national
framework legislation, ethical principles can yet
be operationalised. This will enable social
responsibility to be assumed, which will prevent
privatisation of ethical issues and hence ensure
that core ethical principles are observed. 
If we now turn to some of the EU directives,
we find that there are differences in which ethi-
cal principles they take into account: 
The EU directive on clinical trials on medicinal
products for human use require an ethical eva-
luation to be carried out, and require that this
must be performed on the basis of predefined
ethical considerations (balancing of benefits
and integrity). The directive also meets the
requirement for ethical evaluation to be concre-
te in relation to each individual trial. Against
this, the directive does not require the involve-
ment of lay people following an open consulta-
tive process. In the latest review of the directi-
ve on deliberate release, the preamble states
that ethical considerations concerned with
approval of the release of GM crops are to be
incorporated. However, the directive on delibe-
rate release makes no reference to ethical con-
siderations and does not stipulate the involve-
ment of lay people following an open consulta-
tive process. 
If we consider the four ethical criteria, we also
find significant differences among the regulato-
ry options for translating these into legal
requirements. 
The criterion of economic and qualitative
benefit essentially reflects the ethics of utilita-
rism This criterion entails assessment of any
potential damage and risks, together with
assessment of both economic and qualitative
benefits. An assessment of this nature can be
expressed relatively simply in regulations, and
implemented according to a relatively objectivi-
sed process. The fact that the last-named com-
ponent amounts to an estimate of whether the
benefit to be derived from an application of
genetic engineering would be greater than any
damage or risks is not exclusively a regulatory
problem. Estimations and weighing up of ”pros
and cons” is a common element in much regu-
latory work. However, one difficulty might be
that while a criterion may be already establis-
hed in the human area, and to some extent
also as regards animals (higher living orga-
nisms), it may only have gained scant recogni-
tion in relation to the food product area, i.e.
GM foods and crops. In the last-named area,
the regulatory premise traditionally dictated
that anything that does not carry an unaccep-
table risk of damage to human beings or natu-
re may be placed on the market. This presents
a fundamental dilemma when it comes to intro-
ducing more comprehensive assessments in
connection with product authorisations.
The criterion of integrity/vulnerability and
the criterion of just distribution are probably
the two criteria that present the greatest regu-
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latory challenges. This is primarily due to the
fact that these criteria entail broad estimations,
which can be difficult to standardise on to
ensure that the result of their application meets
fundamental requirements for legal protection,
i.e. predictability. Conversely, it is generally
recognised - at least in relation to certain appli-
cations of gene technology - that the ethical
considerations involved are of great significan-
ce. An obvious example of this is reproductive
cloning, which many find should be banned
because it is a violation of human integrity. In
many other areas, however, there will in all
likelihood be great difference in opinion on
whether the application of a field of gene tech-
nology would be in violation of the integrity cri-
terion. As long as the issue concerns procedural
regulation, however, it should in principle be
possible to incorporate considerations of this
nature also, though as already stated, it will
scarcely be feasible to legally verify that such
criteria have been met.
The criterion of openness and co-determina-
tion is essentially a procedural requirement
that may be identified with relative ease in
regulation in the form of requirements regar-
ding administrative routines and decision-
maker forums. As regards the technicalities of
regulation, the criterion can be translated into
a requirement that the decision entailed must
be made following the involvement of lay peop-
le and in such a way that the decision-making
process is conducted in the public domain.
Such requirements could be operationalised eit-
her at a general level, or in the form of detailed
regulation of authorities’ decision-making pro-
cesses, including the detailing of rules on the
extent to which lay opinion is to carry binding
effect. Standardisation of this criterion may be
expressed either as requirements regarding the
decision-making processes employed by EU
institutions, or as requirements regarding the
decision-making processes of national authoriti-
es. In the last-named case there will presuma-
bly be limits to the detail in which the require-
ments could be prescribed at the EU level.
Finally it should be emphasised that the four
ethical criteria should all be incorporated in any
assessment of gene technology applications.
The final decision should be made by weighing
up the assessment made of each criterion. As
such there can be no question of straightfor-
ward decision-making requirements according
to which just a single criterion or all four crite-
ria must be met, but rather a coherent balan-
cing of one against the other. This presents yet
another problem in standardising on the appli-
cation of ethical criteria in formal regulation. 
Overall, the conclusion has to be that while two
of the ethical criteria may be expressed relati-
vely simply in procedural regulation in substan-
tive terms the two others can be expressed
only in more general terms in regulation. Some
of the ethical criteria thus entail assessments
based largely on estimation. Moreover, there is
the fact that an overall assessment must be
made of all four ethical criteria, which again,
will be based largely on estimation.
The next step is to lay down rules for how the
final outcome of the overall ethical evaluation
should be incorporated in the scientific risk
assessment undertaken in parallel with the
ethical evaluation. Thus, a decision must be
made on how the ethical evaluation and the
scientific risk assessment should be weighted
against each other in a final, official ruling.
The conclusion is thus that it is feasible from a
legal point of view to incorporate ethical criteria
in EU regulation of the application of gene
technology. This may be achieved by operatio-
nalising requirements to that effect in procedu-
ral regulations comprised of the following com-
ponents:
1) a requirement regarding ethical 
evaluation;
2) formulated ethical criteria;
3) including an open process to ensure 
co-determination.
Against that, it will be inordinately difficult for
regulation to prescribe the significance or
impact of ethical evaluation. Nonetheless it is
essential to address these aspects, especially
the question as to how far ethical evaluation
can ”displace” scientific risk assessment both in
a positive and negative sense. This then opens
up for two possible scenarios: A scientific risk
assessment reveals that the application of a
field of genetic engineering might be attended
by a certain degree of risk. If the ethical
assessment finds little objection to authorising
this application, should it then be allowed to
proceed? Conversely we have a scenario in
which a scientific risk assessment reveals that
there is no attendant risk in application of the
field of genetic engineering, while the ethical
assessment questions the justification for
approving the application. How would this sce-
nario be dealt with? 
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In considering this dilemma it is important to
bear in mind that regulation at the EU level is
not driven solely by content-based political
assessment, but also by the general aim of
ensuring uniform laws and thereby a single
market in the EU. This produces two likely con-
sequences. The more that ethical evaluation is
performed at EU level, the more it can rest on
estimation and still produce uniform laws. The
more that ethical assessment is performed at
national level, the more can it take into
account differences in national culture and
values, and the more it can ensure an open
process and co-determination.
Consequently our position is that while incorpo-
ration of ethical criteria in EU regulation is fea-
sible it is also associated with considerable
challenges. Furthermore it may be noted that
regulation will to a large extent amount to pro-
cedural standardisation, and that the consequ-
ences of a decision-making process at the EU
or national level will be significant. The essence
of the conclusions presented here may also be
expressed to say that the incorporation of ethi-
cal consideration in EU regulation concern dia-
logue and decision-making processes just as
much as they do the legal technicalities of
regulation.
Thus is should be expected that there will be a
need for both regulation proper - social ethics
from the top down - and acceptance from sta-
keholders in the broadest sense - i.e. ethics
from the bottom up. Top-down and bottom-up
will, however, be equally important.
Biodiplomacy is one of the new concepts in the
area.
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10 Prospects and
challenges
In the area of human health a number of ethi-
cal principles have now been adopted, but
often after a quantum leap from general mat-
ters of principle to concrete interpretation and
evaluation, in which dialogue and debate for-
ums have often been lacking. 
There is therefore a need for
• national implementation of international 
conventions;
• concrete guidance for administrators;
• dialogue forums among the different 
actors, and
• further scope for public debate.
The tools that serve as aids are the debate
models, but discussion of the regulatory models
and their application will hopefully also serve as
inspiration.
In the foods area it has been more difficult to
elaborate ethical principles since the ”classical”
principles associated with the human area of
dignity, integrity and autonomy do not have
quite the same meaning in this area. The foods
area therefore involves more scientific risk
assessments linked in with the precautionary
principle and the like. Tentative efforts have
been made to get ethical principles associated
with co-determination and openness adopted,
but at the same time, the quantum leap from
scientific risk assessment to ethical evaluation
informed by values has as yet not been made
in this area, perhaps because it is difficult to
get this assimilated in a more market-oriented
and product-based area. 
There is therefore a need for
• crystallising out ethical values in the foods
area;
• incorporating ethical assessments;
• concrete guidance for administrators;
• dialogue forums among different actors, 
and
• further dialogue and debate.
In this area also the debate models should the-
refore be expected to have a significant part to
play in the future, while the regulatory models
especially will be geared to the international
level. 
One concrete proposal might be a general
framework for operationalisation of ethical
principles at EU level:
a) A joint European Commission and
Council of Europe resolution concerning,
which general ethical considerations should
be incorporated in vetting biotechnology appli-
cations and the creation of topical dialogue
forums
b) A joint communication concerning
”good governance” in respect of
decisions/rulings on the application of biotech-
nology - with elements such as scientific risk
assessment, incorporation of ethical considera-
tions, openness, information and debate, the
use of ethics councils along with lay participa-
tion, etc. 
It is difficult to prescribe formulae for ethics
that will allow them to be operationalised - but
it is important to do so - if necessary by practi-
sing on different models.
And it is better to sample the entire ”menu”
than ”go to bed on an empty stomach”. 
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11 Postscript 
In the following we have sought to summarise
the conclusions of the report in a mnemonic
based on the principle which we regard as
pivotal, that is, the need for dialogue:
D Debate - Make room and time for public 
polycentric debate within the forums between
scientists, between decision-makers and 
between lay people. Make sure that there is 
room for disagreement and promote ”coope-
ration despite disagreement”.
I Interdisciplinarity - Academics from diffe-
rent disciplines must exchange experience 
and work towards the creation of a mutual 
understanding and interpretation of and 
implementation of ethical principles in con-
cepts involving biotechnology.
A Agora marketplace - governance and deci-
sion-makers should facilitate the creation of 
an agora, where stakeholders can meet and 
exchange views with each other and the 
public. In ancient Greece the public admini-
stration, the court, the philosophers and the 
traders met here to govern, exchange views 
and do business. In a time where science 
and the application of science is multinational
and will have impact on future generations, 
the creation of agorae should be local, natio-
nal and international alike.
L Learning - Children, young persons and lay-
men as such should be trained in decision-
making with regard to ethical issues, and 
researchers should be educated in ethical 
issues concerning their field of research. 
O Operationalise - Ensure the operationalisa-
tion of ethical principles in politics, regulation
and debate. 
G Gradualism - If we are to go forward then 
we should do so step by step. The principle 
of gradualism should be considered each 
time we have to make decisions that may be
irreversible or may have impact on the envi-
ronment and future generations. 
U Update -Ethics ”just in time” - timing - 
renew and update the deliberations and deci-
sions. Choose the right time for the debate 
of a special issue, not too early and not too 
late.
E Evolution - of ethical principles and their 
specific application to new areas.
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